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ABSTRACT 
Background and Objectives 
HIV/AIDS has posed many unprecedented challenges. It causes a white 
spectrum of disease manifestation. Approximately 60 % of the AIDS patients have 
neurological symptoms and 80-90 % is found to have neuro-pathological abnormality 
at biopsy. The pattern of neurological complication in HIV infection in India is 
different from that of western countries. This study was under taken to 1-Study the 
neurological manifestations in HIV patients admitted in to CMC Hospital, 
Coimbatore 2-to note differences with various studies carried out in other parts of the 
world.  
Methods 
Patents admitted  in CMC Hospital, Coimbatore between August 2013 to 
August 2014  with symptoms referring to nervous system were screened and 
confirmed to have HIV-1 and/or HIV-2 infection (seropositive) by ICTC 
(Trispottest,Trilenetest,Dot immunoassay )were enrolled if they met the inclusion 
criteria. 
 
 
 
RESULTS 
74 of the 672 HIV positive patients fulfilled the inclusion criteria and were 
studied for neurological manifestations (>11 %). 51 were males and 23females with 
F:M ratio 1:2.2  and mean age ranged from 21-51 years. Majority of the patients were 
in economically productive age group. 61% were presenting with neurological 
symptoms and signs for the first time and were diagnosed HIV positive following 
admission. 
 Tuberculosis is the single most common organism affecting CNS( 64%.) 
Headache, fever and altered sensorium were commonest symptoms in HIV patients 
with Neurological pathology. 
CD4 count less than 200 was seen in 24 of  these patients(32%).others above 
200 but below 500.so there is strong association between development of 
opportunistic infection and CD4 count. 
 As compared to western literature CNS TB was the commonest disease 
associated with HIV infections in our study. It was presenting pathology in 68% of 
the cases. It was associated with Pulmonary TB in 10% the cases. 23patients showed 
Space occupying lesion. Mean CD4 Count  observed to be 210.7 
 
 
 
 Interpretation and Conclusion 
There is high incidence of neurological manifestations with tuberculosis and 
Toxoplasmosis being commonest pathogenic agents in course of HIV infections in 
this study. Simple investigations like CD4 count may provide a clue to the degree of 
underlying immunosuppression and indicate the need to start ART in HIV/AIDS 
patients. 
 
Key words 
Human Immunodeficiency Virus; Tubercular meningitis; Cryptococcal meningitis; 
bacterial meningitis; Tuberculoma; CD4 count. 
 INTRODUCTION 
 
 AIDS was first recognized in the United States in 1981
01
. In India 
it was first pointed out in 1986 in Tamil Nadu. 
 
 The HIV/AIDS has posed many challenges. Like the tip of the ice 
and real magnitude of iceberg remains under sea, the real magnitude of 
HIV and AIDS still remains to be evaluated. 
 
 HIV and AIDS cause a wide spectrum of diseases and 
manifestations. Approximately 60 percent of patients with AIDS have 
neurological symptoms and 80 to 90 percent were found to have 
neuropathological abnormalities in autopsy
3
.  Neurological complications 
of HIV infection cause marked morbidity and are often associated with 
high mortality. The pattern of presentation in India appears to differ from 
the world literature in that TB meningitis leads the list of opportunistic 
neurological infections. 
 
 
 
  
AIMS & OBJECTIVES 
 
1) To study various Neurological manifestations of HIV infection in 
patients presenting to the general medicine department at Government 
Headquarters hospital, Coimbatore with reference to the patient’s CD4 
count. 
2) To note the gross and subtle differences in the Neurological 
manifestations of HIV infection in patients in this study with the 
various studies carried out in other countries. 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
EPIDEMIOLOGY OF HIV/AIDS 
Historical Milestones 
 First recognized in the United States in 1981. 
 
 In 1981 Pneumocystis carinii pneumonia (PCP) was 
reported in 5 homosexual men in Los Angeles and of 
Kaposi’s sarcoma in 26   homosexual men in 2 cities of US 
Viz. New York and Los Angeles.
1
 
 
 Both were reported by US Centre for Disease Control and 
Prevention. 
 
 Indication that the disease is caused by a retrovirus came 
first in 1983 from French scientists, when professor 
Montagnier and his co-worker isolated the causative viral 
agent, which was later named as Human immunodeficiency 
virus (HIV).  
 
 ELISA technique to detect the presence of antibodies in 
blood against HIV was developed in 1984. 
 
  In 1986, the Montagnier's group discovered a new type of 
HIV in West Africa and labeled it as HIV-2. 
 
 
  In 1987,for the first time Zidovudine was reported to be 
useful in managing the patient with HIV infection for the 
first time.  
The Global Scenario
6
 
 A global pandemic 
 Al countries have reported HIV cases 
The Indian Scenario
5 
 HIV/AIDS in India was first detected in 1986 in 
Chennai,Tamilnadu and later from Mumbai in 1987. 
  Presence of HIV-2 infection in India was reported for the first 
time from Mumbai in 1991.
8
 
 India is said to have the lowest population with HIV
10
, though 
it has the third largest number of people living with 
HIV/AIDS. Based on HIV Sentinel Surveillance 2008, it is 
estimated that India has an adult prevalence of 0.31 percent
2
 
with 23.9 lakh people infected with HIV, of which, 39 
percent(9.3 lakhs) are female and 3.5 percent are children. , 
while 83 percent are the in age group 15-49 years. It is 
estimated that India had approximately 1.2 lakh new HIV 
infections in 2009
9
. 
 Manipur, with 0.78% of the people having HIV, is the state 
having maximum number of HIV population, followed by 
Andhra Pradesh with 0.76% in the second place, Karnataka 
with 0.69% in the third place and Nagaland in the fourth place 
with 0.66%
8
 
 No new HIV cases  were reported from any states in 2010 
 Most infections occur through heterosexual transmission. 
However, in certain regions use of injecting drug, men who 
have sex with men and single male migrants are contributing 
for the spread of HIV epidemic. HIV epidemic in India is 
found in certain groups. The HIV prevalence among the High 
Risk Groups, i.e., Female Sex Workers, Injecting Drug Users, 
Men who have Sex with Men and Transgenders is about 20 
times higher than the general population. 
 The mode of spread of HIV in the Southern part of the country 
is mostly through heterosexually. Whereas infections in the 
north-east are predominantly from illicit drug injection. 
 
 
 
 Trends of HIV in India, 2004
fig -1Estimated Annual New HIV Infections in india
 
The scenario in Tamil Nadu
  Tamil Nadu, which had an alarmingly high incidence of HIV 
infection even 10 years ago
with the largest number of people infected with the deadly virus.
The state previously ranked in the top three 
people, it has now been overtaken by Karnataka (2.45 lakh), and West 
Bengal (1.67 lakh 
-09
.
 
10 
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, has dropped from third to fifth among states 
with 1.54 lakh HIV
 
 
 
 
 
  
-positive 
HUMAN IMMUNODEFICIENCY VIRUS 
Causative Agent: 
 The causative agent of AIDS is Human immunodeficiency virus 
 Family - human retroviruses (Retroviridae) 
 Subfamily -lentivirus.  
 Types , 
• HIV-1  
• HIV-2. 
 HIV-1-commonest all over the world and in India . 
 Differences between the two are: 
1) The transmission efficiency of HIV-2 infection through 
sexual route is lower when  compared to HIV-1. 
 2) The incubation period of HIV-2 infection is reported to 
be longer than that of HIV-1.  
Of the persons infected with HIV in India, 1.7%-4.6%  due to HIV-
2 alone, and 3.3%-20% due to combined HIV-1 and HIV-2. 
Presence of dual infection of HIV-1 and HIV-2 and not of HIV-2 
alone has also been reported among intravenous drug users from 
Manipur
8
. 
 
 
 
Fig-2 Structure of HIV Virus IV- 
 
 
 
 
 
 
 
 
 
  Icosahedral structure, with a number of external spikes 
constituted  by  
2 major envelope proteins viz.  
o the envelope gp120  
o transmembrane gp41.  
 After entry into cell infected cell’s surface show budding virions 
and integrates various host proteins which includes major 
histocompatability complex (MHC) both classes antigens into 
lipid membrane 
 There are three transcriptive units coding for the common viral 
structural proteins: 
 
 The gag region for the viral core  
 The pol region for the reverse transcriptase,  
• protease,  
• endonuclease 
 The envregion for the 2 major envelop glycoproteins, mentioned 
above. 
 gp120  situated on the external spikes of the virion,  
 gp41 helps in  the attachment  of gp120 on the surface of the HIV. 
 Apart from this structural proteins, other 4 virus encoded 
regulatory proteins have been recognized. They play a role in 
"checks and balances" controlling HIV replication. Viz: 
 Two major genes tat and rev affect the events that enhance viral 
application, whereas 
 The nef region down regulates virus replication.  
 The vif region appears responsible for maturation of viral proteins 
at the time the virus bud from the cell. 
 The early interaction of these regulatory proteins during acute 
infection of a cell by HIV determines the terminal outcome of this 
infection. For example, in the presence of high levels of nef gene 
expression, viral replication could be suppressed. Other viral genes, 
some specific for HIV-1 (vpu) or HIV-2 (vpr) have been 
identified,about their functions have not been fully identified. 
Replication Cycle Of HIV
11 
1. Binding and entry 
 HIV is a RNA virus,  genomic RNA to DNA conversion occurs 
with the help of reverse transcriptase. 
 gp120 protein binds to CD4 receptors on the host cell surface 
which marks onset of replication cycle. 
 it fuses with one of the group of co-receptors 
 Virus enters into specific cells.  
 Other chemokine receptors involved are CCR5 receptors on 
monocytes and CXCR4 receptors on T cells. Strains of HIV 
utilizing CCR5 as a co-receptor are called as R5 viruses, and 
Those strains of HIV utilizing CXCR4 are called as X4 viruses. 
Rarely individuals though had   have sexual exposure to HIV in 
high-risk situations, remained uninfected. Retrospective Genetic 
analysis of these individuals showed an inherited homozygous 
defect in the gene that codes for CCR5. Population study showed 
that 1% of Caucasians of Western Europe in ancestry possessed the 
above homozygous defect. 20% had heterozygous defect. 
Homozygous defect in CXCR4 got the infection but manifested 
slow progression of the disease
1
. 
 
2. Reverse transcription, nuclear import, and integration of viral 
DNA 
 Every virion has  a store of  reverse transcriptase enzyme,  
 Catalyzes the reverse conversion of the genomic RNA into DNA. 
 So formed DNA enters nucleus 
 Integrase adds the formed DNA at random sites of the host cell 
chromosome through,.  
 Provirus produced can be transcriptionally inactive (latent) or may 
actively produce virus. 
3. Assembly of virus 
 Soon after transcription, HIV m-RNA is converted into protein 
 They undergo modification  by glycosylation 
 Then cleavage occurs.  
 The virus constituted by   proteins, enzymes, and  RNA 
 Stay at  cell membrane of  cells.  
 Core acquires its envelop from the membrane.  
 Protease enzyme mediates the conversion of gag-pol precursor 
to form the mature virus particle. 
12
 
  
 
 
 
  Fig-3 replication cycle of HIV 
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MODE OF TRANSMISSION
1 
HIV can be transmitted by 
 Contacts homosexually and heterosexually 
  through blood and its  products; and by 
 from infected mothers to infants either   in intrapartum period, 
perinatal period or while breast feeding. 
Sexual transmission 
  Commonest  transmission mode 
 Developing countries, -heterosexually transmitted, but in 
many western countries male-to-male sexual transmission 
still occurs.  
 Many factors influencing transmission 
a. viral load  
b. ulcerative genital diseases  
 Such transmission  inefficient.  
 Per coital act risk was .12% /act when not on ART  
 In developing  country  high rate in this analysis 
 Female-to-male (0.38% per act and  
 male-to-female transmission 0.30% per act,. 
 HIV detected in semen both inside and outside infected cells . 
 The virus  accumulates in  semen in inflammatory states such as 
urethritis and epididymitis, having numerous  lymphocytes and 
monocytes in the fluid,  
 Virus also  isolated from cervical  and vaginal secretions.  
 High risk of HIV transmission  with unprotected receptive anal 
intercourse (URAI) among both men and women when compared 
to the risk associated with receptive vaginal intercourse. Although 
data are limited, the per-act risk for HIV transmission via URAI 
was estimated to be 1.4% for both men and women in a recent 
systemic review/meta-analysis. 
 Presence of other STDs increases the chance of spread of HIV 
because of ulceration of mucosa eg:  
• Treponema, pallidum,  
• H.ducreyi and  
• Herpes simplex.  
 Studies done in Uganda showed that the main determinant of 
heterosexual transmission of HIV were : 
• amount of virus in blood.  
• If no circumcision done increased risk because more chance for 
micro trauma and increase in other STD. 
•  Oral sex  less efficient mode  when compared to other modes  
• Alcohol abuse with  illicit drug use along with unsafe sexual 
practices both homosexually and heterosexually doubles the 
risk. 
 
Blood and its products 
 HIV-screening done to blood and its products, or organ 
transplantation . 
  sharing of used needles, syringes, the water used for  mixing, or 
the cotton 
 Parenteral transmission occurs with Intra Venous puncture; 
Subcutaneous or Intramuscular  injections , even though these 
modes mistakenly interpreted as low-risk  
 >90% of people get infected . 
 Sources of blood transmitting  HIV  are: 
a. whole blood, 
b.  packed RBCS 
c. , platelets,  
d. irradiated leukocytes, and 
e.  plasma can 
 Exceptions: 
1) hyperimmune gamma globulin,  
2) hepatitis B immune globulin, 
3)  plasma-derived hepatitis B vaccine, and 
4)  Rho immune globulin 
While processing these products there will be inactivation or removal of 
the virus. 
 
Occupational transmission of HIV 
 There is little, but definitive increased risk of HIV transmission in 
health care workers and laboratory workers. Following contact with 
infected materials chances of transmission are: 
 Skin-0.34%  
 mucous membrane - 0.09% if the injured and/or exposed person is 
not treated within 24 h with antiretroviral drugs. 
 through intact skin has not  documented 
 Nonintact skin exposure  reported, but the mean risk ; lesser than 
through mucous membrane exposure.. 
 from infected HIV health worker to patient is very rare, till now 
only four such cases has been reported worldwide. 
Maternal to fetal / infant transmission 
 Infected mother transmits the virus to her foetus during pregnant 
period or at time of delivery.  
 Developing countries- commonest mode of transmission  
 Vulnerable periods of transmission: 
I. first six months of pregnancy-28% 
II. delivery process-60% 
III. breast milk. -25% 
 High chance of infection –earlier   part of breast feeding 
  Exclusive breast-feeding less chance of transmission than mixed 
feeding 
  The first-born twin  more chance of  infection than  second one 
 Caesarean section lowers the risk. 
 18% -developed countries and from 
  28% - developing countries.  
 Greater transmission in 
a) plasma viremia more in mothers,  
b) low maternal CD4+T Cells count and 
c) HIV P24 antibody levels, 
d) maternal vitamin A deficiency, 
e) prolonged interval between membrane rupture and 
delivery,  
f) chorioamnionit is during delivery,  
g) STDs , 
h) preterm labour, 
i) Amniocentesis 
The risk of transmission increases with level of HIV RNA in 
maternal blood, < 1000 copies / ml blood is associated with 0%, 
16.6% among 1000 to 10,000 copies / ml. 22% (10,001 to 50,000 / 
ml), (50,000 to 1,00,000 / ml) and 41% >1,00,000 /. If mother 
suffers from acute primary infection during pregnancy, there is a 
higher rate of transmission to the fetus owing to the high levels of 
viremia. Zidovudine treatment of HIV infected mother (pregnant) 
from the start of the second trimester throughout delivery and for 
the baby for 6 weeks following birth decreases the risk from 25% 
to less than 5%. 
Other body fluids 
 HIV found in low titers in saliva but it would not 
transmit the disease . 
 Innate antiviral factors in saliva; which are 
immunoglobulins like IgA , isotype 
  Another mechanism  sequesteration of virus by mucins 
along with thrombospondin 1 and aggregation and later  
cleared by  host. 
 No virus in tears, sweat, and urine
1.
 
 
IMMUNO-PATHOGENESIS OF HIV/AIDS
12,14 
 HIV infection is unique because host cannot eliminate the virus, so 
chronic infection;   there is simultaneous progressing deterioration of 
immunity. Hence they become more and more immunocompromised 
thereby suffers from dangerous opportunistic infections as well as 
malignancies.
13 
 Primary infection with the human immunodeficiency virus (HIV) 
composes of viremia with or without clinical symptoms to be followed by 
a long period of clinical latency. During this period, there is only little, 
detectable viremia, the number of infected cells in the blood are very low 
and it is extremely difficult to isolate virus from these cells. Pantaleo et 
al
12
, have analyzed viral burden and levels of virus replication 
simultaneously in the blood and lymphoid organs of the same individuals 
at various stages of HIV disease. They reported that in early stage of 
disease, there is a dichotomy between the levels of viral burden and virus 
replication in peripheral blood versus lymphoid organs. HIV disease is 
active in the lymphoid tissue throughout the period of clinical latency, 
even though only minimal viral activity is demonstrated in blood.
14,15 
  HIV persists in the lymphatic tissue stimulates the immune system 
which strengthen virus replication and  virus dissemination follows, 
clearance of newly produced HIV will not be possible
16
. 
Three dominant patterns of evolution of HIV infection are in 
vogue:
15,16 
l) Typical progressors 
• Majority in this group 
• Survival average 10 years
14
. 
II) Rapid progressors 
• Only-10% are rapid progressors
14,16
 
• Rapid  course. 
III) Long-term non progressors 
• Only 5%  
• No progression for long time.
14
 
 
CD4 T cells count
17 
 main targets of HIV infection.  
 a valid marker for the progression of the disease. 
 decrease in CD4 count is due to: 
a) Direct virological mechanism that results from a HIV mediated 
cytopathic effect. (eg: direct killing of cells and syncytial 
formation). 
b) Non-virological mechanism (eg: autoimmune mechanisms, 
anergy, apoptosis, and virus-specific immune responses) triggered 
off during the course of HIV infection
17
. 
 
Stages Of  Infection 
 Entire sequence of events is approximately 7 to 10 years from 
seroconversion to death.  
  The stages are. 
1) Transmission of virus:  acquired through sexual contact, 
exposure to blood or its products, mother to child transmission. 
2) Primary HIV infection (Acute HIV infection or acute 
seroconversion syndrome). Incubation period average 2 to 4 
weeks, maximum up to 6 weeks, characterized by 
mononucleosis or flu-like illnesses. 
3) Seroconversion: takes place at 6 to 12 weeks following an 
established transmission event. 
4) Early asymptomatic phase:, CD4+Tcell counts >500/_l 
• the patient does not have any HIV related symptoms,  
• persistent generalized lymphadenopathy involving 2 or more 
sites and skin manifestations such as seborrheic dermatitis 
present.  
• Plasma viremia is generally low. The viral burden in the 
peripheral blood is extremely low and expression of HIV in 
these cells minimal. 
5) Early symptomatic HIV disease, (CD4+T cells 200 to 
500/microltr): 
• The patients in this stage may have mild features of the 
disease 
• Active replication of HIV virus in this period. 
6) Late symptomatic HIV disease- AIDS, (CD4+T cells 50-
200/microltr): 
• Continuous replication of virus in the lymphoid tissue,  
• Progressive destruction of this tissue (burnt out lymph node) 
and severe impairment of immune function.  
• This stage is characterized by severe and persistent 
constitutional signs and symptoms of opportunistic 
infections or neoplasms or both. Common examples are 
Kaposi sarcoma, PCP, toxoplasma gondii , widespread 
mycobacterium aviumintracellulare  infections,  candidiasis 
of oesophagus, lymphoma.  
 
7) Advanced stage, (CD4 count < 50/microltr): 
 In this stage, patients may have AIDS defining opportunistic 
infections and malignancies. Certain opportunistic infections are more 
likely to occur with profound immune suppression such as CMV retinitis, 
cryptococcal meningitis, disseminated histoplasmosis, etc. Neurological 
disease is more prevalent at this stage of infection
1. 
 
DIAGNOSIS OF HIV INFECTION AND AIDS- INDIAN 
GUIDELINES 
The moral issues  vary from country to country; hence, it is imperative to 
know the national guidelines regarding HIV testing. 
Objectives of HIV testing
 
1. Survey:  the trend of HIV infection monitored in a population for 
intervening. 
2. Safe Transfusion:  blood, organs or tissues for donation. 
3. Voluntary testing of HIV for the purpose of diagnosis 
.4. To diagnose clinically suspected cases. 
5. To evaluate and monitor cases of occupational exposure. 
6. Research. 
The laboratory tests for diagnosis of HIV constitute: 
1. Indirect methods. 
2. Direct methods. 
1. Indirect methods 
 Screening tests. 
 Supplemental tests. 
Screening Tests
19 
Simple/Rapid assays are based on the following 
 
a. Agglutination assays 
High sensitivity, low specificity, requires only few minutes to perform. 
also less expensive as it does not require equipment like ELISA reader. 
b. DOT BLOT assays / COMB test 
 The principle -immunochromatography.  
 The assays are rapid, easy to perform,  
 No need of complicated equipment.  
  Positive- formation of color on a specific circle, dot or a line. 
 
 
 
 
c. ELISA 
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 Screening test. 
  HIV-1 and HIV-2, detection.  
 Sensitivity - 99.7% and the specificity ->98.5%.  
 The first line test recommended by NACO (National AIDS Control 
Organization) 
 
Supplemental tests 
Being more specific than the screening tests, used to confirm screening 
tests are: 
 
a). Western blot. 
 Confirmatory test.  
 Immunoblot test for various types of anti-HIV antibodies by 
blotting technique using a nitrocellulose membrane.  
  Western blot test is only to be used in case of equivocal or 
discordant results of ELISA.,( national HIV testing ) 
b) Indirect immunofluorescence assay
20
. 
 turns positive earlier in the course of the disease than conventional 
ELISA and Western-blot technique. 
c) Radioimmunoprecipitation assay. 
d) Rapid latex agglutination assay ( modification of standard latex 
agglutination test). 
2. Direct methods 
Detection of viral genomic material. 
  (PCR): for specific gene sequence in the middle of many. 
• DNA-PCR - early detection of HIV infection. 
It is a highly sensitive test, (detection of one infected cell per 
1,00,000 cells)  highly subject to the false positivity by means 
of contamination or by laboratory processing error. 
• RT-PCR - measures viral RNA.  
Both qualitative detection as well as quantification are presently 
available, Ultrasensitive RT-PCR assays have a detection limit of 
50 copies per ml., Quantification or measurement of viral load is an 
essential parameter for initiation of antiretroviral therapy as well as 
for monitoring the therapeutic response. 
 NASBA (Nucleic Acid Sequence Based Amplification) 
HIV-1 RNA may be quantified by RNA amplification using 
electrochemical luminescence. 
 b-DNA- Branched DNA technology detects HIV RNA directly 
through amplification of signal from a captured viral genome. 
 P24 antigen capture assay. There is brisk rise during initial weeks 
of infection.  
 
• this test has greatest use as a screening test for HIV infection 
during acute HIV syndrome when P24 level is high before the 
development of antibodies.The disadvantage antigenemia is 
transient, limiting its detection. 
 Viral culture. 
• Expensive and labour intensive.  
• Adherence to sterile technique is very crucial.  
• Peripheral blood mononuclear cells are -cultured with 
uninfected donor cells with phytohemagglutinin for 3 days.  
•  Monitored every 3 days for 28 days or longer to assess: 
a. the formation of syncytia and  
b. Presence of HIV P24 antigen or RT in culture 
supernatants. 
WHO/Govt. of India Strategies to detect HIV infections. 
 Since there is a great risk for transmission of HIV through blood, 
screening of blood products is mandatory.  
 Following strategies  put forward by WHO for detecting HIV 
infection  , they are:  
Strategy I - ensuring donation safety. The serum is subjected once to 
ELISA; if negative, patient won’t have HIV, if positive, blood not used, 
and the donor is not informed.  
Strategy II - for surveillance and for the diagnosis only in the presence 
of some AIDS-indicator disease: if first ELISA is negative, the sample is 
considered negative. If positive, second ELISA done, utilizing a 
technique different. Result positive only if second ELISA is also positive. 
Strategy III - for diagnosing asymptomatic individuals with high-risk 
behaviour, a third ELISA test reactive then HIV positive. 
In resource-limited countries, the testing strategy can be followed which 
is less expensive and easy to perform. Under these circumstances, there is 
no need to confirm the ELISA/Rapid test/Simple test results by 
supplemental tests
18
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fig-4 Showing objectives of testing  
 
National Guidelines for Adults
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1) Symptomatic people: reactive with two different kits .  
2) Asymptomatic people:  three different kits reactive 
3) Blood sample collected at a time is tested with the first kit. If  reactive, 
then retested  with the second then third kit. 
 The kits that are used in ICTC are: Trispottest, Trilenetest, Dot 
immunoassay .  
 
CDC classification system 
 The current CDC classification system is used for HIV-infected 
adolescents and adults  
 Parameters are  clinical conditions due to HIV infection and CD4+ T 
lymphocyte counts.  
 Three ranges of CD4+ T lymphocyte counts and three clinical 
categories 
  those with CD4+ T cell count of <200/L has AIDS by definition, 
irrespective of  opportunistic diseases . 
 Once  in category B, it cant  goback to category A, even if the 
condition resolves; it is applicable  for category C
1
  
 
Definitive AIDS diagnosis.(with or without lab diagnosis of HIV 
infection)
1 
 Candidiasis of the oesophagus, bronchi, trachea, or lungs  
 Extrapulmonary Cryptococcosis,  
 Cryptosporidiosis, diarrhea>1 month 
 Cytomegalovirus disease of an organ other than liver, spleen, or 
lymphnodes 
 Herpes simplex: mucocutaneous ulcer(s) (>1 month's duration); or 
bronchitis, pneumonitis, or esophagitis of any duration 
 Kaposi's sarcoma <60 yrs 
 Lymphoma, primary, of brain <60 yrs age 
 Mycobacterium avium complex or M. kansasii, disseminated or 
extrapulmonary 
 Mycobacterium tuberculosis, any site (pulmonarya or extrapulmonary)   
 Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary 
 Pneumocystis jiroveci pneumonia  
 Progressive multifocal leukoencephalopathy 
 Toxoplasmosis brain 
  
fig 5:Relationship of  CD4 Count  Development of  
Opportunistic Infection 
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Drugs used in treating HIV
21 
Antiretroviral agents act at vary steps of the life cycle disturbing 
replication of virus. : 
(i) fusion inhibitors-inhibits fusion of virus with cell 
(ii) reverse transcriptase inhibitors-block enzyme reverse transcriptase  
(iii) inhibit enzyme- integrase,  
(iv) Blocking  synthesis of  viral protein 
(v) Blocking protease enzyme-(protease inhibitors) 
(vi) prevention of budding virions from getting detached from cell 
 
Commonly used agents  
1) reverse transcriptase  inhibitors 
2) protease inhibitors 
3)   fusion inhibitors 
4) . New classes of drugs are under trial. 
 
 
 
 
 
 
 
Fig 6
 
MONITORING OF HIV INFECTION
Follow-up and monitoring is required for
watch clinical progress and monitor
counts  is the best valida
infection among patients with HIV infection. 
independently determine prognosis
risk of specific opportunistic infec
plasma viral levels. T
not include criteria based on plasma 
 
 
 
 
  Classes of ARV drugs
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 information with regard to AIDS, the 
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 related to 
Fig 7 Mon
 
 LFT to be monitored every month for HIV patients coinfected with 
HCV. 
 
 Fasting lipid profile done hal
derangement. Especially 
artery disease. 
 
 
itoring toxicities for patients on ART
21
f  yearly since  PIs can cause lipid 
In patients with history of    coronary 
 
 
 Viral copies need not be routinely measured. it is only indicated 
when there is a disparity between clinical findings and CD4 count 
so that treatment failure can be assessed. 
 
 Patients on ART should have TheirCD4 count for patients  ART 
should be measured at 6 monthly interval 
 
 Drug-induced hepatitis can be caused by nevirapine so LFT 
mandatory in 1
st
 month 
 
  With an AZT cause bone marrow suppression. So CBC to be done 
 
 RBS estimated before and after starting ART since diabetes 
mellitus is a leading cause of morbidity.  
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HIV and Neurologic Diseases
3,4 
Neurological disorders affecting HIV patients accounts for 
increased morbidity in a good number of patients with HIV infection. The 
neurologic disorders that develop may be either primary to the 
pathological processes of HIV virus or secondary to opportunistic 
infections or neoplasms. It can affect both central and peripheral  nervous 
system. 
Fig 8 Neurologic Diseases in  HIV Infected people
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NEUROPATHOGENESIS
13 
 HIV-infected individuals can develop various  neurological 
abnormalities due either to opportunistic infections and neoplasm 
or to direct effects of HIV or its products.  
 Referring  to the latter aspect, virus isolated from brain tissue and 
CSF of these people with and without neuropsychiatry 
manifestations.  
 The cell types which are mainly infected  in vivo are monocytes  
migrated to  brain from the  blood as well as  microglial cells 
originally residing there.  
 
 HIV entry into brain is postulated to be  partially, : virus infected 
cells are able to stimulate expression  molecules for adhesion like 
E-selectins and  (VCAM-1) on brain endothelial cells in brain 
vasculature. 
 another mechanism:  HIV gp120 increases the expression of  
(ICAM-1) in glial cells; by which HIV-infected cells enter inside  
CNS and resulting in syncytium complex. Virus isolates from the 
brain are preferentially R5 strains as opposed to X4 strains; with 
respect to this , 
  HIV-infected people having heterozygosity for CCR5D32  
protectedfrom HIV encephalopathy compared to those who have 
homozygosity for the same. 
 HIV-infected individual showed lesionsin white matter as well as 
neuronal loss in neuroimaging. Given the relative paucity of     
supporting evidence of HIV infection in neurons either in vivo or 
in vitro, it .Rather, the HIV-mediated effects on brain tissue are due 
to  combination of neurotoxins secreted by monocytes and 
inhibition by gp120, reytes. In this regard, it has been demonstrated 
that both HIV-1 Nef and Tat can induce chemotaxis of leukocytes, 
including monocytes, into the CNS. Neurotoxins are usually 
released from monocytes as a result of infection and/or immune 
activation. neurotoxic factors secreted by monocytes have been 
reported to kill neurons through (NMDA) receptor.  
 In addition, HIV gp120 cause neurotoxicity by 
1) opposiing action of  (VIP), 
2)  raising intracellular calcium , and 
3)  diminishing nerve growth factor level 
 A variety of monocyte-derived cytokines can contribute both  
directly as well as indirectly ; these include TNF-α, IL-1, IL-6, 
TGF-β, IFN- γ, platelet-activating factor, and endothelin. In 
addition, infection and/or activation ofmonocyte-lineage cells can 
result in increase in eicosanoids, ,andquinolinic acid, which may 
contribute to neurotoxicity. 
 It has been found out that HIV-infected individuals with the E4type 
allele inapolipoprotein E (apo E) have greater chance  
encephalopathy and  neuropathy features 
 The probability that virus and its products are responsible for 
neuropathogenesis is evidenced by the observation that 
neuropsychiatric abnormalities may undergo remarkable and rapid 
improvement upon the institution of ART, particularly in children 
affected with AIDS.
1
 
 
 
CLINICAL FEATURES 
 The nervous system - frequent and severe targets of (HIV) 
infection. 
  75% of all persons infected with HIV develop 
symptomswith respect to neurologic diseases. As stated 
above Neurologic disease in  HIV infected population is not 
only common but also it is frequently both catastrophic and 
life-endangering.  
 Neurological disease occurs with advanced 
immunosuppression  and patient has other  (AIDS)-defining 
illnesses,  
  15% of HIV seropositive persons it is the presenting feature 
of AIDS. 
  Carefully scrutinizing CNS examination, even without the 
presence of definite problems pertaining to neurological 
involvement, frequently shows evidence  central or 
peripheral nervous system involvement. 
 Any portion of the neural network may be involved by a 
wide variety of neurologic diseases complicatingHIV-1. 
Illnesses affecting the nervous system due to HIV may be 
classified into primary illnesses directly due to virus and 
secondary illnesses, due to identifiable causes. Primary HIV-
associated disorders include brain-encephalopathy 
(dementia), spinal cord-myelopathy, peripheral nerve-distal 
sensory polyneuropathy (DISP), and muscle-myopathy. 
Secondary complications are mainly as the result of cell 
mediated immunity deficiency accompanying AIDS. The 
main infectious complications are 
1) cerebral toxoplasmosis,  
2) cryptococcal meningitis,  
3) Cytomegalovirus (CMV) infection,  
4) Progressive multifocal leukoencephalopathy 
Other causes of neurologic disease include neoplasms both primary and 
metastsasis, drug toxicity, metabolic and nutritional diseases, and 
stroke.
23
  
 
PRIMARY HIV-ASSOCIATED DISORDERS OF CNS
4 
HIV Encephalopathy / AIDS Dementia Complex 
The term AIDS Dementia complex was introduced by navia and 
colleagues in 1986.HIV-associated dementia is the forerunner of AIDS-
defining illness in a minority (3%) of patients with HIV infection and 
hence only rarely precedes clinical evidence of immunodeficiency. 
Clinically significant encephalopathy gradually develops in 25% of 
untreated patients with AIDS. As immunologic function declines, the risk 
and gradation of HIV-associated dementia goes on rising. Autopsy series 
conducted  suggests that 80–90% of patients with HIV infection have 
histologic evidence of CNS involvement
1
. 
Clinical Features 
 most prevalent form of the neurologic complications of HIV –  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9-CT brain of HIV dementia-dilated ventricles, cerebral 
atrophy 
 
 
 
 
  
Fig 10-screening of HIV DEMENTIA 
 
 
 Other terminologies ( AIDS dementia complex: , HIV 
encephalopathy, multinucleate giant cell encephalitis, o: HIV-1- 
accompanied cognitive/motor complex).  
 The symptoms of HIV dementia - three main categories:  
a) Cognitive, forgetfulness, sluggish activities, difficulty reading, 
concentration decrease. 
b) Motor, imbalance and limb weakness. 
c) Behavioural. – Lack of interest , social withdrawal,   depression 
is a close differential diagnosis.  
 Acute mania could be a first manifestation. Early , signs   subtle to 
make a definite  diagnosis.  
 As dementia progresses, the more marked cognitive impairment 
develop psychomotor retardation as well as marked behavioural 
abnormalities can occur.  
 At terminal stage, they develop paraparesis, incontinence,:tremor, 
or seizure,  
 The onset and progression   varies. Commonly, dementia occurs 
lately 
 CD4 lymphocyte counts are usually below 200/mm. 
  At times, first AIDS-defining illness 
 Neurologic deficits progress either rapidly or slowly. 
 How early neuropsychologic impairment occurs is controversial: 
whether subtle neurocognitive deficits precede the development of 
HIV dementia. 
 
Diagnostic Studies 
 To date no laboratory tests or neuroimaging study have been  found 
to be  specific for diagnosing HIV dementia, 
  After  excluding other causes we establish the diagnosis 
  Blood VDRL and 
 Cerebrospinal fluid for cryptococcal antigen). 
  CSF abnormalities :             
a) elevated total protein, 
b) pleocytosis,  
c) globulin positive due to intrathecal synthesis 
d) oligoclonal bands. 
 (Similar CSF picture in neurologically asymptomatic patients with HIV 
infection.)  
 Other  dementia causes ruled out,  
 Elevations of CSF B2-microglobulin, , and quinolinate,  connected 
with the HIV dementia,  
  Radiologic studies to rule out infections or neoplasms and 
supporting  evidence of HIV dementia 
  Neuroimaging  shows  
a) Cerebral atrophy,  
b)  Enlarged ventricles,  
c) White matter abnormalities.  
All these are nonspecific, there seem to be importance for volume of the 
cerebrum that has undergone atrophy( more the atrophy on brain (MRI) 
more  severe  magnitude of dementia). 
 
Pathogenesis 
 The clinical features show that there is predominant involvement of 
structures of subcortex , as evidenced by neuroimaging . The cause of 
cerebral atrophy is likely to be due to multiple factors, although there is 
an association between the ventricular expansions revealed by computed 
tomography (CT) scans. Microglial cells are increased in the cerebral 
cortex. Tyor and colleagues have proposed a unifying hypothesis for HIV 
dementia and several other neurologic disorders associated with HIV 
infection. They suggest that the abnormalities observed in HIV dementia, 
vacuolar myelopathy and sensory neuropathy are the consequence of 
infiltration of the CNS by macrophages and microglial with subsequent 
release of toxic cytokines, such as TNF and IL. 
 
 
 Neuropathologic abnormalities depicted are                                     
a)  inflammatory cell infiltration  
b)  glial cell infiltration
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,  
c) widespread pallor in white matter . 
d)  Pallor could be due to 
a) demyelination,  
b) alterations in BBB.  
 HTLV) type III (HIV-l) is the cause of dementia, due to HIV 
gp41dendrites with their synapses are destroyed .Polymerase chain 
reaction magnifies HIV DNA. 
 Connection  between viral copies and encephalopathy  found out 
 Cells affected by HIV are:  
a. Monocyte/macrophage series 
b. Endothelial cells . 
c. Glial cells in pediatric AIDS encephalopathy. 
d. Astrocytes, 
 Gpl20 cause death of neurons in vitro accompanied by the opening 
of calcium channels in cell membrane requires microglial cells. 
CCB- nimodipine prevent neuronal death  
 Monocytes and astrocytes produce neurotoxic factors leading to 
glial proliferation. 
 Cytokines, like TNF-α and IL-6, and arachidonic acid metabolites 
cause neurotoxic damage.  
 Stimulation of N-methyl-D-aspartate (NMDA) receptors, just like 
other neurodegenerative disorders. Furthermore, Heyes and 
colleagues have demonstrated increased levels of the excito-toxin 
quinolinic acid; an NMDA agonist. 
Fig 11      HIV Encephalopathy-stages
1 
Stage Definition 
0 (Normal) Normal mental and motor function. 
0.5 
(Equivocal/subclinical) 
Absent, minimal, or equivocal symptoms 
without impairment of work or capacity to 
perform activities of daily living. Mild 
signs (snout response, slowed ocular or 
extremity movements) may be present. 
Gait and strength are normal. 
 
1 (Mild) Able to perform all but the more 
demanding aspects of work or activities of 
daily living but with unequivocal evidence 
(signs or symptoms that may include 
performance on neuropsychological 
testing) of functional, intellectual, or motor 
impairment. Can walk without assistance. 
2 (Moderate) Able to perform basic activities of self-care 
but cannot work or maintain the more 
demanding aspects of daily life. 
Ambulatory, but may require a single prop. 
3 (Severe) Major intellectual incapacity (cannot follow 
news or personal events, cannot sustain 
complex conversation, considerable slowing 
of all output) or motor disability (cannot 
walk unassisted, usually with slowing and 
clumsiness of arms as well). 
4 (End-stage) Nearly vegetative. Intellectual and social 
comprehension and output are at a 
rudimentary level. Nearly or absolutely 
mute. Paraparetic or paraplegic with 
urinary and fecal incontinence. 
 
 
Treatment
3,4 
 HIV plays vital role, direct or indirect, in the pathogenesis of HIV 
dementia. Thus, soon after antiretroviral therapy became available, 
patients with HIV dementia was put on the same                .  
 Zidovu-dine (ZDV)used in adult HIV dementia and retarded the 
progression of encephalopathy in children. . 
 Eearly treatment with ZDV is said to protect from cognitive 
impairment in AIDS. 
 Dose of the   prophylaxis: not yet determined 
 AIDS patients receiving ZDV 1000 mg/day improved 
neuropsychologic performance compared to the patients. Hence 
higher doses used. 
 If dementia progressing after administering high doses then 
stavudine [d4T] 40 to 80 mg/day may also be given in zidovudine 
intolerance. 
 Although there are limited data to indicate the efficacy of this 
approach, improvement in neuropsychiatric test scores have been 
noted for both adult and paediatric patients treated with 
antiretrovirals. With initiation of Cart quick resolution of cognitive 
dysfunction shows that soluble mediators are involved in the 
pathogenesis and that problem is reversible. It is also worth 
mentioning that these patients have an increased sensitivity to the 
side effects of epileptic drugs. Using these drugs for symptomatic 
treatment is associated with an increased risk of extrapyramidal 
side effects. Therefore, patients with HIV encephalopathy who 
receive these agents must be monitored carefully. Several 
experimental agents are under investigation in the treatment of HIV 
dementia, including nimodipine (calcium-channel blocker), 
memantine (NMDA antagonist), delavirdine and peptideT
22 
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Myelopathy 
 20% of patients with AIDS present with myelopathy, often as part of 
HIV-associated neurocognitive disorder 
. Three main types of spinal cord disease are seen in patients with AIDS.  
1. vacuolar myelopathy. 
Vacuolarmyelopathy  characterized by usually a subacute onset 
and often presents with gait disturbances, mainly ataxia and 
spasticity; 
Which   later  may progress to include bladder and bowel 
incontinence. 
 Physical findings include : increased deep tendon reflexes and 
extensor plantar responses.  
2. The second form of spinal cord disease involves the dorsal columns 
presents as a pure sensory ataxia.  
3. The third form is also sensory in nature  
presents with paresthesias and dysesthesias of the lower extremities.  
Autopsy showed Myelopathy   in 38% of total cases .  
 
 
Causes of myelopathy : 
 toxoplasma,  
 lymphomatous, 
 granulomatous myelitis,  
  necrotizing myelitis, due to varicella zoster 
 Cytomagalovirus, and  
 vitamin BJ2 deficiency.  
 Diagnosis: 
a. MRI of brain with spinal cord screening  
b. CSF examination  
( for ruling out  infections and neoplasms.) 
Pathology 
 Direct: vacuolization in myelin , due to deposition of  
macrophages and glial cells. 
 Indirect: through cytokines, particularly TNF. 
 Although more important mechanism could be the metabolic 
deficits occurring more distal in the B12 utilization pathway . 
Treatment 
 There is no known treatment for AIDS-associated vacuolar 
myelopathy. 
 Antiretroviral agents do not appear to offer benefit, although 
controlled trials have not been done. 
 The methionine, a critical substrate in the B12 metabolic pathway, 
is under trial in the management of AIDS myelopathy.  
 Specific therapy : 
antispasticity agents (i.e. baclofen), 
treatment of sphincter disturbance 
physiotherapy.
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Peripheral Neuropathy 
Distal Symmetric Polyneuropathy  
 most common form .  
  rarely early in the course of HIV disease,  
 risk increases with declining CD4 cell counts. .            
 clinical or electrophysiological anomaly only 35% ; but  
 pathologic evidence of DSP 90% 
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 The presenting features in DSP : 
•  numbness  
• burning sensation and  
• foot paresthesias 
• severe that patients experience pain on contact  and  walking 
difficulty 
• later distal muscle weakness developes 
 CNS examination : pain and thermal loss in palms  and soles , 
absent proprioception, and sluggish ankle reflexes increased 
knee reflexes. 
 The mechanism - unknown. 
Pathology: 
 dying back neuropathy 
 affects all types of fiber,  
 peripheral nerve infiltration with predominent macrophage 
along with  TNF-α, IL-1, and other 
 many other cytokines involved.  
Conditions causing DSP, : 
 vitamin deficiencies (B6, vitamin B12)  
 diabetes  
 alcohol abuse. 
 Drugs like vincristine and antiretroviral nudeoside analogues 
didanosine (ddl), zaldtabine (ddC), and stavudine (d4T) . 
 those past history of neuropathy subclinically more susceptible. 
 cumbersome to differentiate between drug induced neuropathy  
and  HIV  induced. Numb feeling, tingling sensation,  lancinating 
pain common to both  
 distal extremities mainly affected, severety more in the lower 
limbs,  upper extremities spared till late . 
  DSP may evolve slowly, whereas drug induced neuropathic 
symptoms progress more rapidly. 
 Improvement of symptoms after drug cessation. 
 
Treatment 
 Reduce doses of ART 
 analgesics, tricyclic antidepressants- Amitriptyline, 
antiepileptics
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 acupuncture  under trial. 
 
INFLAMMATORY DEMYELINATING POLYNEUROPATHY 
Inflammatory demyelinating polyneuropathy (IDP) presents as 
 Ascending type of weakness, 
 Absent reflexes   
 Less of sensory disturbance 
 Like GBS or CIDP as seen in seronegative patients. 
  Develop in early part of HIV  
 some present at the time of seroconversion . 
IDP occuring late CMV should be thought of  as a cause. 
 
 
 
Diagnosis: 
CSF: 
pleocytosis in HIV-infected patients with IDP, whereas HIV-
negative patients tend to have albuminocytological dissociation in 
cerebrospinal fluid. 
Treatment 
Since IDP is most likely mediated by autoimmune mechanisms and 
has responded, in many uncontrolled series, to immunomodulaters, 
including corticosteroids, plasmapheresis, and intravenous 
immunoglobulin.  
 
Progressive Polyradiculopathy (PP) 
 The presenting symptoms : are 
• Paraesthesia in leg and sacral area,  
• flaccid weakness of lower limb, 
•  absent reflexes,  
• Loss of sensation,  
• Retention of urine. 
Diagnosis : 
 CSF shows pleocytosis, - lot of neutrophils 
 cerebrospinal fluid culture is positive   50% 
 primarily due to CMV infection of nerve roots. 
Treatment:  
 before irreversible necrosis of the nerve root sets in treatment 
instituted 
 improvement in neurological status or stabilization  with 
gancicyclovir. Other causes of  progressive polyradiculopathy in 
AIDS : 
• syphilis,  
• lymphoma, in leptomeninges 
• tuberculosis.
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Mononeuritis Multiplexa 
 multifocal, asymmetric, lesions involving both  
 cranial  nerves-facial or vocal cord palsy  
 peripheral nerve lesions, as for example, -wrist drop or foot 
drop, 
 tingling symptoms. 
  initial stages of HIV infection, disease process confined to one 
or few nerves  
 subsides on its own without any treatment. 
 as HIV disease advances,  CD4 counts goes below 50 
cells/cumm, progress quickly to quadriparesis. 
 misdiagnosed as IDP, DSP, .  
 extensive form of mononeuropathy multiplex due to CMV virus 
and gancyclovir therapy
22
 produces some improvement.
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Myopathy 
Clinical Features 
HIV-associated myopathy develope irrespective of CD4 count. 
• Proximal muscle weakness, -cannot get up from  chair or climb 
stairs.  
• Myalgia a nonspecific symptom in HIV infection.  
• Loss of weight  
• can be a reason for HIV wasting syndrome.  
 
Diagnosis:  
• Creatine kinase (CK) - most sensitive serologic test CK is 
increased in   myopathy,  average of 500 U/L.  not by itself 
diagnostic of myopathy. The presence of proximal muscle 
weakness,along with supporting electrophysiological, is 
necessary for the specific diagnosis of myopathy,  
• Electromyography (EMG) - useful in doubtful cases.  
• muscle biopsy in HIV-associated myopathy can also be 
considered which  display less interstitial inflammation than 
that present in HIV-negative polymyositis. Other  findings in 
HIV myopathy are  
A.  inclusions,  
B. nemaline bodies, 
C. cytoplasmic granules,  
D. mitochondrial anomalities
23
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Pathogenesis 
 The pathogenesis - unknown, although 
 immune mechanisms same as HIV-negative polymyositis. 
 infect monocyte/macrophage lineage cells, myofiber infection 
has not been detected.  
 other opportunistic infections causing myopathy : 
• parasite-Toxoplasmosis 
• virus-CMV,  
• fungus-Microsporida, Cryptococcus neoformans,  
• Bacteria-Mycobacteriumavium-intracellulare and 
Staphylococcus aureus. 
• Drug induced myopathy -ZDV.  ZDV toxicity level contributing 
to underlying  myopathy not known 
• And whether there are distinguishing features controversial.  
Morgello and associates
39
 reported a quantitative morphologic 
study in which the degree of mitochondrial abnormalities was 
similar in patients treated or untreated with ZDV and was with 
regard to the extent of myofiber degeneration. Red ragged fibers 
are a histologic hallmark of zidovudine-induced myopathy.(HH) 
 
MR spectroscopy, cytochrome C oxidase deficiency, mitochondrial 
DNA abnormalities, have shown evidence for drug induced myopathy 
and animal models. 
 
Treatment 
 Patients with severe limb weakness should be subjected to 
withdraw the drug or reduce the dose. ZDV-treated patients that 
showed subjective improvement in muscle strength after ZDV 
discontinuation varies among between 18% to 100%. , a minority  
improves with ZDV withdrawal, .  
 Prednisone therapy can be used,  
 . Patients with or without inflammatory infiltrates responds to 
steroid  
 oxandrolone, an anabolic steroid, resulted in weight gain, but not 
objective strength improvement, in patients with HIV myopathy 
and wasting syndrome 
 
 
SECONDARY HIV-ASSOCIATED DISORDERS OF 
NERVOUS SYSTEM 
Mycobacterium Tuberculosis 
 Tuberculosis is the most commonest  HIV related opportunistic 
infection in India  contrary to p.carini in western countries. A 
study from Western India showed 57 out of 64 HIV seropositive 
cases as having tuberculosis 
 Immunosupressed individuals and immunocompetant have 
difference in clinical presentation  
 diffuse infiltrates in lung or mediastinal lymphadenopathy, more 
of extrapulmonary involvement 
.
 
         HIV infected individuals can develop any  form of 
tuberculosis, especially developing extrapulmonary tuberculosis 
,example tuberculous meningitis  more  chance.
.
 HIV infection 
progresses more  in patients hastenly with tuberculosis. the risk of 
developing active tuberculosis increased by a factor of 15 to 
30.Unusual predilection in the form of lower lobe involvement, 
extrapulmonary affection, diarrhea, and meningitis are common in 
HIV patients.  
• 669% chance  tuberculosis  in AIDS cases in a recent study, 
where 54.5%  atypical. Progression of disease result in CD4 
lymphocytes decline  in quantity and quality; hence immune 
system  can’t arrest the multiplication and  spread of 
mycobacterium tuberculosis. 
•
 Commonest form of extrapulmonary disease is:
 
I.
 lymphadenopathy
 
II.
 pleural effusion, Serous effusions are more 
common
 
III.
 pericarditis
 
IV.
 miliary disease, 
 
V.
 bone involvement
 
VI.
 meningitis. 
 
CNS involvement: M. Tuberculosis can cause  
 meningitis, 
 tuberculoma,  
 brain abscess, 
  myelopathy, or  
 radiculopathy. 
 It can occur at any stage of HIV infection, and is often 
intracerebral and accompanied by anergy to skin testing. central 
nervous system involvement in patients with tuberculosis was five 
times higher in seropositive than in seronegative patients. Patients 
present with insidious onset of headache, fever and malaise, 
followed by meningismus, cranial nerve deficits, seizures and 
altered mental status. meningeal signs were absent in one third of 
these patients, and altered mentation was present in less than half. 
 HIV-infected patients with tuberculosis more chance for 
meningeal involvement, no change in clinical manifestations or the 
course of TB meningitis. 
  prognostic factors in TB meningitis  
I. clinical stage at presentation.  
II.  duration of illness,  
III. miliary disease,  
IV. Using alcohol ,  
V.  age,  
VI. racity,  
VII.  basilar meningitis  
VIII. vascular compromise 
IX. low CD4 count. 
 

 No alteration in presenting  features except for
 
I.
 Severe cognitive dysfunction   in HIV-affected 
patients. 
 
II.
 basal meningeal enhancement and hydrocephalus 
not commonly seen 
 
III.
 fewer basal exudates and numerous tb bacilli in 
cerebral cortex and layers of meninges . 
 
IV.
  lower leukocyte counts in  blood and CSF fluid 
 
 When M.tuberculosis affects the intracranial arteries stroke results 
,  anterior circulation is the most common site.  
 A patient with AIDS who have a focal CNS lesion without focal 
neurological signs are more likely to have Toxoplasmosis than 
Tubeculosis. In patients with Mycobacterium avium intracellulare, 
single or multiple mass lesions are more common than meningitis. 
Computed tomographic characteristics are diverse and include 
ring-enhancing lesions , infarcts. rarely, the CSF  normal. Negative 
microbiologic studies of the CSF are not unusual, resulting in 
treatment for presumptive infection. Meningeal or brain biopsy 
may be required to firmly establish the diagnosis. The response of 
AIDS patients to the standard therapy M tuberculosis is generally 
gratifying 
 
 
                                         
Fig 12-tuberculoma 
Toxoplasmosis 
 Manifest as cerebral mass lesion . 
 incidence of 3% to 40%.  
 the reactivation of  old acquired endogenous infection showing 
lack of IgM antibodies in patients.   
 multicentric lesions and choroid plexus lesion -hematogenous 
spread of parasites from systemic organs  
  developes when CD4 counts goes below 200cells/cumm, 
 the AIDS index- Central nervous system toxoplasmosis usually 
results and it is the diagnosis in half of the cases. 
Clinical Features 
 Toxoplasma encephalitis
47,48
  present with either focal or 
generalized. 
 headache (55%), 
 confused state (52%),  
 fever (47%), 
  tiredness(43%), and  
 convulsions29%). 
  Focal neurological deficits;,  
I. hemiparesis, 
II. falling while walking, and  
III. palsy of cranial nerve. 
  encephalopathy usually develop focal neurological deficit with 
evolving diesease 
 subacutely progression.  
Diagnosis: 
  CT brain- show single or multiple ring enhancing lesions. 
 a higher number of lesions  is shown in MRI studies  and, in 
some cases, show abnormalities  unrecognized by CTscans.  
 Serum anti-Toxoplasma antibodies are  measured,but low or 
absent titer does not rule out the diagnosis. 
 in patients with antibodies to the organism more chance for 
having cerebral toxoplasmosis than who are negative for the 
antibodies .sensitivity more with  Immunofluorescence 
assay than enzyme-linked immunosorbent assay for 
detecting antibody. 
  Polymerase chain reaction of the cerebrospinal fluid may be 
a promising tool in the diagnosis of cerebral toxoplasmosis. 
 thallium single-photon emission computed tomography or 
18F-fluorodeoxyglucose positron-emission tomography can 
be done to rule out  central nervous system lymphoma. 
 
 
 
 
 
Fig 13-toxoplasmosis in brain 
Treatment 
 with large mass lesions producing midline shift with 
herniation, decompression can be done. , 
 empiric therapy started for those people with CT/MRI 
findings consistent with toxoplasma and rising titre of 
antibodies to the organism . 
 oral pyrimethamine  and sulfadiazine . Standard treatment 
with above regimen with leucovorin(5 to 10 mg/day)  is 
required for atleast minimum of 4 weeks  since former 
produce bone marrow depression. Adverse effects of 
sulfadiazine, are rash and nephrotoxicity, seen in 44% of 
patients.  
 Clindamycin(2.4 g/day)  and pyrimethamine 75 mg/day  can 
also be used for Toxoplasma encephalitis. 83%  showing 
improvement of symptoms in  seven days of regimen.  
 stereotactic brain biopsy done, if no clinical or radiological 
improvement in  2 weeks of empiric therapy for,  other 
diagnosis should be sought . 
Prophylaxis: 
 primary prophylaxis: CD4+ T cell counts <100/L and IgG 
antibody present 
 Secondary prophylaxis/maintenance therapy for people with 
history of prior toxoplasmic encephalitis since Relapses can  
occur, -sulfadiazine, pyrimethamine, and leucovorin when 
their CD4+ T cell counts go <200 cells/L. and it can be 
stopped when CD4+ T cell counts  is maintained to >200/L 
for 6 months. 
 the same everyday dose of -a double-strength tablet septran 
given for P. jiroveci prophylaxis ,gives  protection for 
toxoplasmosis as well..
1,22,48
  
 
 
Cryptococcal Meningitis 
 Cryptococcal meningitis is the meningitis caused by fungus  
 very common in HIV-infected patients in .in India. 
 Generally occurs in more than 5% of patients with advanced 
disease in whom CD4+ T cell counts are below 100/microltr. 
The causative organism, Cryptococcus neoformans, may induce 
only little inflammation in AIDS patients with decreased 
immunity 
 There is paucity  of   neck stiffness and photophobia, which 
favour meningeal involvement.  
Clinical features: 
 fatiguebilty,  gastrointestinal disturbance,  
 headache in majority
,
.  
 Cranial nerve palsies 
  psychiatric disorders, 
 Aphasia 
 seizures . 
Diagnosis:(CSF is the specimen used for all the tests mentioned below) 
 India ink stain is used to establish diagnosis of Cryptococcal 
meningitis :CSF is the specimen, 
 Titre of Cryptococcal antigen - 1:8  
 cerebrospinal fluid culture. 
Treatment: 
  Intracranial hypertension managed by  lumbar punctures, 
VPshunt and acetazolamide 
 acute infection:  IV amphotericin B, or liposomal 
formulation of amphotericin, with flucytosine 25 mg/kg qid 
for at least 2 weeks and, if possible, until the CSF culture 
turns negative.  fluconazole 400 mg/d PO *8 weeks, and 
then fluconazole 200 mg/d until the CD4+ T cell count has 
increased to >200 cells/L * 6 months.  
   fluconazole and itraconazole advantage 
a. Less adverse effects so can be used for 
longer duration to prevent relapse. 
Adverse effect: 
I. Amphotericin B -  fever and  glomerulonephritis  
rarely leukoencephalopathy. A liposomal form of 
amphotericin B doesn’t produce above side effects.  
II. Flucytosine bone marrow depression and 
gastrointestinal disorders. 
 
 
 
 
 Primary Central Nervous System Lymphoma 
 Earlier days rare occurence, but now incidence has risen over past 
one decade 
 . more prone to develop in those with CD4 counts < 100/cumm. 
 
Diagnosis: Epstein-Barr virus in AIDS related PCNSL tissue as well as 
CSF, detected by polymerase chain reaction
. 
 
Clinical features: 
  confusion, lethargy, and memory loss,  
 often associated with  headache and focal neurological signs.  
Diagnosis: 
 CT/MRI reveal single or multiple homogeneously ring enhancing 
lesions. Close differental diagnosis   is toxoplasmosis , single 
lesion on MR imaging, with no antibody against toxoplasma 
establishes lymphoma 
 stereotactic biopsy for  Definitive diagnosis 
 
Prognosis: PCNSL in
month  in the case of 
neurological status as well as 
months with  therapy 
Treatment 
Radiation therapy combined with
evaluated in prospective clinical 
Non-Hodgkin's Lymphoma
The AIDS-associated lymphoma
metastases to the central nervous system by non
which are typically meningeal rather than intraparenchymal. Neurological 
. 
 
 
 
 
 
 
 
 
 
Fig 14 primary cns lymphoma 
 AIDS bad prognosis wont survive more than
untreated cases. Radiation therapy may improve
life’s qualityPatient can live upto 4 to 8
 chemotherapy is currently being 
trials. 
 
’s neurological complication
-Hodgkin's lymphoma, 
 a 
s 
 
 is 
disease may either herald the tumor, or the latter may remain occult 
despite repeated lumbar punctures. 
Clinical feature: Affected individuals may present with 
• altered cognitive function,  
• cranial neuropathies,  
• or spinal root lesions,  
•  meningeal lymphomatosis and carcinomatosis seen in 
the absence of HIV infection.  
Diagnosis: In addition to repeated 
 cerebrospinal fluid analyses,  
 bone marrow biopsy and 
 abdominal CT.
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Progressive Multifocal Leukoencephalopathy 
 causative agent-JC virus,a human polyyoomavirus.  
  HIV infection is the most common immunodeficient state 
predisposing to PML, In a review of 150 cases of PML from south 
Florida seen between 1981 and 1994, two occurred with diseases 
other than HIV infection
.  
 Four percent of patients with AIDS 
develop PML during the course of illness, but 29% of these cases 
represented the initial manifestation of AIDS. 
 
 
Clinical features: 
  altered sensorium,  
 speech and decreased vision,  
  difficulty walking, 
  Weakness of limbs 
Diagnosis: 
 CT scans typically show hypodense, non enhancing lesions, most 
common location parietal and-occipital lobe without oedema.  
 MRI- investigation of choice in PML lesions ,T2- weighted spin-
echo. 
 PCR  for JC virus DNA . 
Prognosis: 
 average survival : 2 - 4 months.  
  8%  benign course, can have any of the three ,remission, survival, 
or spontaneous recovery.  
 Good prognosis: 
a.higher CD4 counts (>200 cells/mm3),  
b. CT-contrast enhancement  
c. HPE-inflammatory infiltrates . 
 
 
 
  
 
 
 
 
 
 
 
Fig 15- Progressive Multifocal Leukoencephalopathy 
 
Treatment: 

 no specific treatment 
 

 average survival - 2 years and
 

  seldom survival  >15 years with PML on cART
 

 . Despite having a significant impact on survival, only 50% of patients 
with HIV infection and PML show neurologic improvement with 
cART. Studies with other antiviral agents such as cidofovir have failed 
to show clear benefit. 
 

 favorable prognosis for PML in  HIV infection include a
 
I.
 CD4+ T cell count >100/L 
 
II.
 HIV viral load of <500 copies per milliliter.
1 

 There is only limited information about treatment
 

 Intravenous cytarabine (Ara-C) tried. .in a analysis of the first 
60 patients enrolled in this trial failed to show efficiency of Ara-
C in the treatment of AIDS-associated PML Several 
chemotherapeutic agents have been documented to have in vitro 
antiviral activity against the JC virus, including camptothecin 
and topotecan; however, both are toxic and await evaluation in 
clinical trials. 
 

 despite  widespread use of Cart PML still possible
 .1 
 
Cytomegalovirus: 
CMV can result in a constellation of central As well as peripheral 
nervous system disorders in AIDS, : 
• CMV encephalitis,- a cause of dementia in AIDS patients 
 Seen in patients with  CD4 count < 50 cells/cumm 
 
. 
 common pathologic finding in  brain - microglial nodule , rarely  
o CMV inclusions. 
 Common targets- brain stem and spinal cord . 
 Adrenal glands are also affected.  
 associating other infections 
a) toxoplasmosis 
b) zoster 
c) Cryptococcus 
d) PML 
•  myelitis,  
 polyradiculopathy, and 
 mononeuropathy multiplex.. 
 
Clinical Features 
 close differential diagnosis : HIV dementia.  
 Sudden altered sensorium 
 more brain stem involvement 
 
Diagnosis: 
 CT scan: hydrocephalus ,periventricular or meningeal 
enhancement.  
 retinal fundi :any CMV retinitis. 
 Electrolyte abnormalities due to adrenal failure 
 specific serologic or laboratory tests not available for confirmation  
of CMV encephalitis 
  reliable investigation: polymerase chain reaction for CMV DNA 
Treatment 
 average survival time for CMV encephalitis -5 weeks,  
 antiviral therapy no role 
 drugs: ganciclovir or foscarnet. 
  Only 38% Ganciclovir  penetrates   blood-brain barrier 
 Alternate drug: foscarnet 
 A current research is evaluating the utility of polymerase chain 
reaction measures of CMV DNA in the cerebrospinal fluid and 
the efficacy of antiviral agents in the therapy of these disorders. 
Syphilis 
 Is also a differential diagnosis of neurological disease in HIV-
patients 
  Overlap of neurological diseases in retrovirus and spirochaetes 
Clinical features: 
 acute meningitis,  
 neuropathies of cranial and peripheral nerves, 
 memory problem; 
 stroke, and  
 spinal cord diesease.  
Diagnosis: 
 :both produce alike CSF picture,- persistent pleocytosis.  
 Although   cerebrospinal fluid VDRL positivity is diagnostic of 
syphilis,  sensitivity - 30% to 70%. In those with symptoms 
suggestive neurosyphilis having positivity of serum VDRL, 
negative cerebrospinal fluid VDRL,  intravenous high-dose 
penicillin can be instituted . with a negative cerebrospinal fluid 
VDRL treatment given 
a. protein exceeds 65 mg/dl  
b. cerebrospinal fluid pleocytosis is greater than 20 
cells/cumm.
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c.  HIV infection alone cannot produce this picture 
 Elevated cerebrospinal fluid IgG or cerebrospinal fluid 
oligoclonal bands on electrophoresis are present in both HIV 
infection and neurosyphilis and therefore are not likely to be 
diagnostically helpful.  
Treatment: 
 Those having HIV infection no adequate response to usual 
treatment rather, accelerated progression of neurosyphilis. 
 aggressively treat syphilis in the HIV-affected patient. 
  aqueous penicillin G (12 to 24 million units/day) ten days- 
treatment of choice 
 response to therapy assessed by Serum and cerebrospinal fluid 
testing .  
 Follow up-2 years 
  aim- CSF values , VDRL titers should normalize 
  cerebrospinal fluid abnormalities may persist due to simultaneous 
HIV infection.retreatment if the cerebrospinal fluid profile does not 
improve or deteriorates or if clinical symptoms suggestive of 
neurosyphilis development. 
MATERIALS AND METHODS 
 
STUDY AREA 
General ward, ICU, General Medicine OPD, ART Centre and 
Neurology OPD of Government Coimbatore Medical College Hospital 
(CMCH), Coimbatore, a tertiary care centre in south India. 
STUDY POPULATION 
The subjects of the study will be all adult HIV patients admitted to 
Medical Units with Neurological manifestations during the study period 
and alsoHIV Patients Reviewed at the ART Centre and Neurology OPD 
at CMCH with Neurological manifestations developed after the diagnosis 
of HIV, presenting to the clinic during the study period who fulfil the 
inclusion criteria. 
Inclusion Criteria: 
1. All adult HIV patients with neurological manifestations presenting 
to CMCH, Coimbatore who are willing to take part in the study. 
2. The subjects must have been an already diagnosed case of HIV, 
before developing the neurological manifestation. 
 
Exclusion Criteria: 
1. Patients not willing to take part in the study 
2. Patients with pre-existing neurological disease, psychiatric 
patients, children and pregnant women.  
3. Newly detected cases of HIV, where the neurological complaints 
were the presenting features or suffering from the neurological 
manifestations before the diagnosis of HIV. 
4. Patients with other Neurological problems unrelated to HIV 
(neuro-degenerative diseases, neuro dystrophies  )  
5. Patients with co-existent Hep B and Hep C infections. 
SAMPLE SIZE: 
The sample size for the study is obtained using the equation:  
 
n = ( 
Zα

  + 
Z
1  β )
2   
xσ
2 
 δ
2
 
where 
Zα

   1.96 at 5% level of significance 
Z1  β  0.482 at 80% power 
σ   Assumed standard deviation 
δ   Desired precision 
   = (1.96 + 0.842)
2
  x  (2.1)
2 
 = 71 samples 
        (0.7)
2
 
STUDY DESIGN: 
A cross-sectional study. 
STUDY INTERVENTION: 
Our study will be conducted in the General ward, ICU, General 
Medicine OPD, ART Centre and Neurology OPD of Government 
Coimbatore Medical College Hospital (CMCH), Coimbatore. Over the 
study period of 12 months, all adult patients, who fulfils the inclusion 
criteria will be enrolled in the study. The diagnosis of HIV will be 
defined as per the National Aids Control Organisations criteria. 
 Along with initial routine assessment, written informed consent 
will be obtained from eligible patients/ their relatives. They will undergo 
the treatment according to their clinical status. 
 The patients are free to discontinue from the study at any point of 
time according to their will and there will be no change in the treatment 
instituted to them irrespective of their willingness to continue/discontinue 
from the study. 
 
STUDY DURATION:-  
1 year 
DATA COLLECTION FORM 
(Enclosed in Annexure I) 
STATISTICAL METHODS 
 The statistical analysis will be carried out using the software SPSS 
version 22.0. All the data will be expressed as Mean ± Standard deviation. 
Comparison of the means will be done using the unpaired T test or Mann 
Whitney U test. One way ANOVA will be applied to compare the 
different means. A p-value <0.05 will be considered as significant. 
DATA COLLECTION TECHNIQUE AND TOOLS 
 The data was collected from the eligible subjects in the data 
collection form after obtaining the informed consent. The data was then 
entered in Microsoft Excel sheet. For statistical purposes, the data was 
transferred to SPSS software and the analysis and charts were prepared. 
 
 
 
 
OBSERVATION & RESULTS
 
Sex Ratio 
The sex ratio of the subjects in the present study is 
 
 
Table 2
Male
Female
Combined
 
 
 
Female
23
31%
Chart 1: Sex ratio of study population
 
1:2.2 
TABLE 1: SEXRATIO 
Male Female 
51 23 
- Average age of the study subjects 
Sex Average Age 
 33.27451 
 33.43243 
 33.69565 
 
Male
51
69%
Male
Female
 
Table : 3 Age & sex wise distribution of study 
Age group
18-25 
25-35 
35-45 
45-55 
 
 
 
Table
 
Coimbatore 
TamilNadu but outside Coimbatore
South INdia other thaN TamilNadu
North INdia
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Chart 2: Age & sex wise distribution of study 
subjects 
 Total Males Females 
9 5 4 
40 29 11 
23 16 7 
23 1 1 
 : 4 Nativity of the study subjects 
  
Nativity 
Number of 
subjects 
54 
 12 
 5 
 3 
Females
Males
25-35
35-45
45-55
Sex of the subject
Age group
subjects
 
Females
Males
Table :5
 
Male
Female
Total
 
• 86% married ,43 males,21 females
• 10 unmarried 
 
12, 16%
Chart 3: Nativity of the study subjects
 Marital Status of the study subjects 
Single Married 
 8 43 
 2 21 
 10 64 
 
(54) 73%
5, 7%
3, 4%
Coimbatore
TamilNadu but outside 
Coimbatore
South INdia other thaN 
TamilNadu
North INdia
 
  
TABLE 6: 
 
New cases
Old cases
 
Married
Chart 4: Marital Status of the study 
0
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Chart 5: Sex
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already diagNosed old cases 
 
Number of cases 
 45 
 29 
SiNgle
10
14%
64
86%
subjects
SiNgle
Married
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SiNgle
Married
2
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8
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-wise marital status of 
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 OCCUPATION 
OccupatioN 
Skilled labourer 
UNskilled labourer 
House wife 
Driver 
StudeNt 
House-maid 
ProfessioNal 
MigraNt labourer 
Self employed 
 
Old cases
29
39%
Chart 6: Ratio of newly detecetd & 
already diagnosed old cases
TABLE 7: OCCUPATION 
OF THE SUBJECTS 
Male
s 
Female
s
19 2
12 5
0 9
8 0
4 2
0 4
3 1
3 0
2 0
New cases
45
61%
New cases
Old cases
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 4 
 4 
 3 
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TABLE 8: MODE OF 
MODE OF TRANSMISSION TO THE SUBJECTS
Mode of transmission
Sexual 
Multiple 
Unknown 
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Chart 7: Occupation of the study 
Sexual
64
86%
Chart 8: MODE OF TRANSMISSION TO THE 
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• Sexual transmission most common
• Other  routes-transfusion of blood,
prick etc  
 
TABLE 9: DISTRIBUTION OF STUDY SUBJECTS BASED ON 
Symptoms 
Weight loss 
Fever 
Headache 
ALTS 
FND 
Convulsions 
Vertigo 
 
 
 
• Most common symptom fever
• Second most common altered sensorium
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Chart 9: 
SUBJECTS BASED ON SYMPTOMS
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Table: 11 Frequency of deranged
Frequency of deranged vitals in study subjects
Vitals 
Number of 
subjects 
36
 
AbseNt
64
86%
Chart 10: History of pulmonary TB
 : 10 History of Pulmonary TB 
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 Table: 12 CNS Abnormalities in the study subjects
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Chart 13: Frequency of CNS abnormalities in 
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Chart 14: Frequency of anbormality 
 : 14 Abnormality in fundus 
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Table:16  RELATIONSHIP BETWEEN CRANIAL NERVE 
INVOLVEMENT & CD4 COUNT
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Table:18 RELATIONSHIP BETWEEN MENINGISM & 
CD4 COUNT 
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Mean CSF protein level is 132.9mg/dL
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Chart 20: CSF Protein levels
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10
20
30
40
A
0
No: of subjects
Chart 21: CSF Sugar levels
 CSF Sugar Levels 
CSF Sugar levels 
Sugar (mg/dL) Frequency 
<40 25 
41-60 32 
>60 10 
Mean CSF sugar is 46.7mg/dL 
Table : 22 CSF cell count 
CSF cell count 
CSF cells Frequency 
9 
 58 
 
Mean CSF cell count is 210.64 
B
C
0
0
32
10
Sugar (mg/dL)
Frequency
Sugar (mg/dL)
 
Distribution of study subjects based on CD4 count
Table:23
CD4 COUNT
<50 
51-100 
101-200
>200 
 
Mean CD4 count for the study  subjects is 210.70 cells/
P value:.001 so development of neurological manifestations in HIV 
strongly associated with low CD4 count.
0
10
20
30
40
50
60
70
A
9
No: of subjects
Chart 22: CSF Cell Count
 Distribution of study subjects 
based on CD4 count 
 FREQUENCY 
7 
7 
 10 
50 
µL 
 
B
0 0
58
Cell count
Frequency
CSF cells
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 Table:2
Diagnosis
Bacterial Meningitis
Bells Palsy
Cryptococcal Meningitis
CNS Tubercloma
CVA 
GBS 
PML 
Myelopathy
TB Meningitis
TB Meningitis with 
pulmonary TB
Cerebral Toxoplasmosis
 
 
0
<50
51-100
101-200
>200
CD4 count 
(cells/µL)
Chart 23: Distribution of study subjects based 
4 Various diagnosis in the study 
subjects 
 Frequency % 
 5 6.76% 
 1 1.35% 
 2 2.70% 
 3 4.05% 
6 8.11% 
1 1.35% 
1 1.35% 
 1 1.35% 
 38 51.35% 
 
7 9.46% 
 9 12.16% 
10 20 30 40
7
7
10
Number of subjects
on CD4 count
 
50
50
Table:
CD4 Count (cells/µL)
<50 
51-100 
101-200 
>200 
 
Total number of subjects with bacterial meningitis = 5
Mean CD4 count of subjects with bacterial meningitis = 111.2 cells/µL
P value <.oo1:high  association  of CD4 count with Bacterial 
meningitis. 
 
0
20
40
No: of stdy subjects
Chart 24: Various diagnosis in the study 
25 Bacterial Meningitis 
 Frequency % 
2 40.00%
1 20.00%
1 20.00%
1 20.00%
 
Diagnosis
subjects
 
 
 
 
 
 
Frequency
 CNS Tuberculoma 
Number of study subjects with CNS tuberculoma is 3.
The mean CD4 count of subjects with CNS 
cells/µL 
 P value:.001 so association of CNS tuberculoma
count is significant 
CVA 
TOTAL = 6/ 
Mean CD4=  429.33cells/µL
 
101-200 
cells/µL
20%
>200 cells/µL
20%
Chart 25: Distribution of study 
subjects having Bacterial Meningitis 
with regard to CD4 count
 
tuberculoma is 178.67 
 development and  CD4 
 
 
<50 cells/µL
40%
51-100 cells/µL
20%
<50 cells/µL
51-100 cells/µL
101-200 cells/µL
>200 cells/µL
 
Table: 26
CVA with regard to CD4 count
CD4 Count 
<50 cells/µL
51-100 cells/µL
101-200 cells/µL
>200 cells/µL
 
P value :.04-there was 
CD4 count 
 
TUBERCULOSIS ETIOLOGY FOR NEUROLOGICAL 
MANIFESTATION IN HIV PATIENTS
Various tuberculous
Table: 
Diagnosis 
TB Meningitis
TB Meningitis + Pulmonary TB
CNS Tuberculoma
TOTAL 
83%
Chart 26: Distribution of study subjects 
having CVA with regard to CD4 count
 Distribution of study subjects having 
 
(cells/µL) Frequency % 
 0 0 
 0 0.00% 
 1 16.67%
 5 83.33%
 association between development of stroke and 
 
 etiologies 
27 Various tuberculous etiologies 
No: of 
subjects 
 38 
 7 
 3 
48 
0%
17%
<50 cells/µL
51-100 cells/µL
101-200 cells/µL
>200 cells/µL
 
 
 
 Table:28
CD4 count
101-200 cells/µL
>200 cells/µL
 
 
 
TB Meningitis
TB Meningitis + Pulmonary TB
CNS Tuberculoma
Diagnosis
>200 cells/µL
89%
Chart 28: Distribution of subjects 
having TB Meningitis with respect to 
 TB Meningitis & CD4 count 
 No: of subjects 
 5 
 40 
0 5 10 15 20 25 30 35 40
38
7
3
No: of subjects
Chart 27:Various tuberculosis 
etiology for neurological 
manifestations in HIV patients
101-200 
cells/µL
11%
CD4 count 
101-200 cells/µL
>200 cells/µL
 
 
Number of patients with TB meningitis is 45. 
Mean CD4 count in patients with TB meningitis = 222.02 
Number of patients with TB meningitis having concomitant pulmonary 
TB is 7. 
Mean CD4 count in patients with TB meningitis having concomitant 
pulmonary  TB is 212.86 
P value:.002-so association was present between occurrence of TBM 
and CD4 count. 
Table:29 CEREBRAL TOXOPLASMOSIS 
CD4 count Number of patients 
<50 cells/µL 5 
51-100 cells/µL 3 
101-200 cells/µL 1 
>200 cells/µL 0 
 
Total number of patients with cerebral toxoplasmosis is 9. 
Mean CD4 count in patients with cerebral toxoplasmosis is 53.11 
P vaue .001-so there was  association  of low CD4 count   and 
development of toxoplasmosis 
Table:30 Etiology for neurological presentation in 
patients with CD4 count >200 cells/µL
Diagnosis 
Bacterial Meningitis
Bells Palsy 
CNS Tubercloma
cva 
gbs 
TB Meningitis
 
0
5
<50 cells/µL
5
No: of subjects
Chart 29: Distribution of patients 
with cerebral toxoplasmosis in 
 
 
No: of patients 
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 40 
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 Table:31
presentation in patients with CD4 count 
Diagnosis
Bacterial Meningitis
Cryptococcal Meningitis
CVA 
PML 
TB Meningitis
TXM 
 
 
Bacterial Meningitis
Bells Palsy
CNS Tubercloma
cva
gbs
TB Meningitis
Chart 30: Etiology for neurological 
presentations in subjects with CD4 
 Etiology for neurological 
101-200 cells/µL 
 No: of patients 
 1 
 1 
1 
1 
 5 
1 
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1
1
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5
1
Number of subjects
count >200 cells/µl
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 Table:32 Etiology 
patients with CD4 count 51
Diagnosis 
Bacterial Meningitis
Cryptococcal Meningitis
CNS Tubercloma
Myelopathy 
Cerebral Toxoplasmosis
 
0
5
No: of subjects
manifestations in patients with CD4 
for neurological presentation in 
-100 cells/µL 
 
No: of patients 
 1 
 1 
 1 
1 
 3 
Etiology
Chart 31: Etiology for neurological 
count  between 101-200 cells/µL
No: of patients
 
Table:33  Etiology for neurological 
patients with CD4 count <50 cells/µL
Diagnosis 
Cerebral 
Toxoplasmosis
Bacterial 
Meningitis 
 
 
 
Cerebral 
Toxoplasmosis
43%
Chart 32: Etiology for neurological 
manifestations in patients with CD4 
count between 51
Bacterial 
Meningitis
2
29%
Chart 35: Etiology for neurological 
manifestation in patients with CD4 
presentation in 
 
No: of patients 
 
5 
2 
Bacterial 
Meningitis
15%
Cryptococcal 
Meningitis
14%
CNS Tubercloma
14%
Myelopathy
14%
-100 cells/µL
Cerebral 
Toxoplasmosis
5
71%
count <50 cells/µL
Cerebral Toxoplasmosis
Bacterial Meningitis
 
 
DISCUSSION 
AGE GROUP:   
In the present study the age group of patients with neurological 
manifestations ranged from 18-55 years and the mean age observed in 
males was 33.27 years and females was 33. 43 years, with 33.69 years 
being that of the entire study population. 
The largest number of people with HIV infection falls in the age 
group of 25-35 years with males 29 in number and females 11, in this 
group. 
All the study subjects were in economically productive group. 
NACO has reported that disease mainly affects 15-45 years. Mcarther et 
al studied a group of 200 patients in the age group 20-45 yrs and found 
that the mean age was 35 years for males and 37 years for females. 
Stricter et al in a study of 60 patients in the age group 20-70 years 
reported the mean age of 37 yrs. 
The female:male sex ratio in the present study is 1:2.23. Of the74 
patients with HIV,51 were males and 23 females. John et alina study 
conducetd at CMC Vellore, found a  sex ratio of 5:1 for male: females in 
his study. S it can et al noticed a sex ratio of  4:1 (male: female).  
It can be observed that females are a lesser number inmost of the 
hospitals because they are confined to household activity, less social they 
are, C so don’t get admitted. 
MODE OF TRANSMISSION 
 Sexual  route was found to be the most common route, 
 Heterosexual transmission, occupying larger number, 
 A small group has multiple routes of transmission and rest  
unknown mode of source, multiple routes include blood and 
blood products, surgery, contact with sex workers, multiple 
partners and sex workers are major  routes of transmission, 
but in western countries in a study by lee et al found that 
homosexual route is most common, hence this difference is 
due to difference in culture and practice, also they follow 
different types of  sexual practice. 
PRESENTATION: 
   61% presented to our hospital with many neurological manifestations 
and subsequently during the course of hospital stay found to be HIV 
reactive. Rest were  diagnosed as reactive elsewhere 
Lewy et al in a study conducted in US had 25% of his patients with 
neurological symptoms at presentation. 
 
MARITAL STATUS 
         86% of the HIV reactive patients were married, 
 
 
OCCUPATION 
Almost all the people  in the low socioeconomic strata involved in the 
immoral sexual practices  acquired this infection in my study Labourers 
were the largest group with this infection. 
 SYMPTOMS AND SIGNS 
Table:34  CNS SYMPTOMS IN HIV PATIENTS 
Symptoms Present study Sircar et al
72
 
Headache 55 65 
Altered sensorium 62.16 36 
FND 25.68 33 
Convulsion 27.3 28 
 
Altered sensorium was the most common complaint .(34 cases of  
TBM&2 cases of CM).followed by headache 55.41%,convulsion 27.03% 
and focal neurological deficit was observed in 25.68% 
                     Weight loss with fever was most common presentation of 
HIV.It was observed that even if neurological system was not 
involved.Headache can be a presenting complaint.Headache could be due 
to meningitis or due to HIV headache. 
In the study fever was present in 80% and weight loss in 29.7% which 
includes 36 patients with CNSTB and 4 cases of cryptococcal meningitis 
 
NATIVITY: 
54 of my patients have come from Coimbatore.They are residents 
here working in lower socioeconomic  strata.Only  three were    from 
North india who have come here seeking job. 
CLINICAL MANIFESTATION: 
         Among the clinical manifestation it meningism was the commonest 
manifestation, all were having meningitis 18 of them were TB meningitis, 
rest were bacterial, and cryptococal meningitis, 
Meningism was present in 35 patients and 25 had CD4 count 
>200,as the immunosupression was more when counts got  reduced, 
classic signs of meningitis were lacking as in the case of cryptococcal 
meningitis. 
Fundus was abnormal in 11 people, 7 had papilloedema, 4 had 
haemorrhage. 
Tb meningitis and other space occupying lesions can produce 
increase in ICT  thereby papilloedema. 
 
 
 
 
 
 
                                       CSF ANALYSIS 
 We did not attempt CSF studies for 7 people since they had 
papilloedema 
 Mean CSF protein level was 132.9mg/dl.Since most of the cases 
were TB meningitis,CSF proteins were raised to higher levels,but 
in bacterial meningitis not raised to that extent.In GBS there was a 
albuminocytological dissociation 
 Mean CSF sugar level was 42.16 mg/dl.It was low in bacterial 
meningitis<30 mg/dl.in TB meningitis mostly in the range of 40-60 
mg/dl. 
 Mean cell count was 210.67 in tb meningitis was upto 470,whereas 
in other bacterial mengitis it rose upto 1000.In GBS,no cells were 
detected. 
IMAGING 
Total 50 cranial CTs and  3 MRI was done. 
 30 Cranial CT’s were normal. The most common abnormality was 
cerebral edema found in 10patients; inflammatory exudates in 8, 5 had 
hypodense lesion suggestive of infarct ,1 hemorrhage,single ring 
enhancing lesion in 3, multiple lesions in 9. Hydrocephalus in 1. All mass 
/ enhancing lesions were diagnosed to be either tubercular granuloma or 
toxoplasmosis.Based on clinical, CSF analysis and treatment response. 
  3 MRI taken from suspected myelitis cases showed the following 
changes suggestive of demyelination in thoracic spinal cord,1 showed 
white  matter demyelination in parietal region,and 1 was normal. 
     Levy et al
70
 have reported 7 patients (5.46%) of AIDS with 
cerebrovascular complication - 4 with infarcts (due to endocarditis). 
Mc.Arthur et al
65
 reported 9 cases (7%) of Cerebrovascular accidents 
(infarcts and Haemorhage). Snider et al
66
 reported 6 (12%) cases and 
postulated granulomatous angitis as probable eitiopathology. Wadia et 
al
63
 in their study in Pune observed mass lesions in 16 % of the patients, 
single lesion in 24 and multiple lesions in 38. In the study by Puccioni et 
al
77
 ,16 % had ring- enhancing lesions, 18 % had non-enhancing lesions 
and 8 % had normal cranial CTs. 
 
 
 
 
 
 
 
                    NEUROLOGICAL MANIFESTATIONS 
                             CNS TB: 
HIV increases TB infection by 2 folds while AIDS increases by 5 
folds
78
.  
Findings: The commonest neurological complication of HIV 
infection in this study was due to tubercular involvement of the nervous 
system. It was seen in 45 patients (60.817%). Of them, 45 had tubercular 
meningitis, 3 had intracranial tuberculomas. The diagnosis was made 
Table no: 35 comparision of neurological manifestations 
 This study 
n=58 
 
Levy et al
70
 
n=315 
Snider et 
al
66
n=50 
Mc 
Arthur
65
 
n=186 
A. Infections     
Tubercular meningitis 60.81 % <1 % - 1 % 
Cryptococcal 2.7% 13% 4% 6% 
Meningo encephalitis - 34 % 36 % 23 % 
Cerebellitis - - - - 
Myelitis 1.35 % 1 % - 4 % 
PML 1.35% 2 % 4 %  
Bacterial meningitis 6.76% - - ---- 
Gullian barre syndrome 1.35% -- _- ---- 
B. Intracranial mass 4.05 % 10 % 14 % 17 % 
Lesion Tuberculom Lymphoma lymphoma 
C. HIV encephalopathy - - - 7.3 % 
D. Primary Vascular 8.11% 1.5 % 6 % <1 % 
E. Other 
Bell’s palsy 1.35% 3 % - - 
Toxoplasmosis. 12.16% 32 % 10 % 8 % 
P. Neuropathy - 6 % 16 % 5 % 
Myopathy - <1 % - - 
based on clinical, imaging CSF analysis. 
           CT scan was done in 40,10 showed cerebral edema,inflammatory 
exudates in 8, multiple lesions in 1, single enhancing lesions 
in2,hydrocephalus in 1 and rest were normal 
• Mean CD4 count in TB meningitis :212 
• Out of which 5 had count in between 100-200. 
• 40 had count above 200 
• P value was 0.002 relation between CD4 count which was 
statistically highly significant.There was positive correlation 
between occurance of TB Meningitis and CD4 count.      
• 3 had tuberculoma ,mean CD 4 count-178.67,all were below 200. 
• P value was 0.001 which was statistically highly significant with 
positive correlation between occurance of tuberculoma and 
CD4 count. 
  
Table No 36 COMPARISON OF MEAN CD4 COUNT 
 PRESENT 
STUDY 
Madid et 
al n=40 
 
LEWE ET AL
 
renguer et 
al
79
n=37 
TB MENINGITIS 212 230 250 217 
CVA 428 -455 -480 450 
CM 111 155 160 190 
TXM 53.11 89 90 100 
TUBERCULOMA 178.61 180 168 180 
BELL’S PALSY 270 222 230 220 
GBS 210 200 240 190 
MYELOPATHY 79 100 139 120 
PML 170 180 143 180 
BM 236 254 290 270 
MEAN 236    
                         
CRANIAL NEUROPATHIES 
8 patients in this study had cranial nerve palsy. It involved 7th nerve 
in all cases.  causes were  CNS TB (meningitis)(3), tuberculoma-1,4 due 
to CVA, one Bell`s palsy. Mc. Arthur et al65in their study found four 
patients with cranial neuropathies, these of them having facial nerve palsy 
due to aseptic meningitis and one due to lymphomatous meningitis. Levy 
et al70 in their study of neurological involvement of HIV infected 315 
patients detected 8 cases of cranial neuropathies and 25 cases of 
peripheral neuropathies, 5 patients had Bells palsy. Wadia et al,63 
reported Herpes Zoster  of the 457 patients studied. 
• Mean CD4 count with cranial nerve involvement was 234 cells. 
         4 had count above 200,other below 200. 
• P value-.06-No significant correlation found between the  
cranial nerve involvement and CD4 count. 
 
MYELOPATHY / MYELITIS 
Spinal cord involvement in form of Myelitis was seen  only in one 
patient, who presented with flaccid paraperesis with definite sensory level 
and sphincter disturbance of subacute onset.  MRI of the spine showed 
abnormal signal intensities in thoracic cord, suggestive of demyelination 
• Mean CD4 count  was 79 cells. 
Levy et al in a group of 70 have reported a case of necrotizing ascending 
myelitis, which resulted in complete quadriplegia. Culture of CSF in this 
patient yielded CMV. Milligo et al64 reported Myelitis 8% in his study in 
’99 in France.  
 
                   CEREBROVASCULAR ACCIDENT / STROKE 
             In this study 6  cases presented with stroke,2 cases had right sided 
hemiparesis and  their  4 had left sided hemiparesis. Facial nerve was 
involved in 4cases. all 5 cases were infract , one hemorrhage was noted. 
Mc. Arthur et al
65
 reported 9(7%) cases of Cerebrovascular accident. 
Levy et al
70
 have reported 7(5.46%) cases of AIDS with Cerebrovascular 
complications – 4 cases with infarct. 
Mean CD4 count was 429 cells. 
5 had counts above 200,one within 100-200. 
P value was .04 which was significant statistically showing positive 
correlation between development of stroke and CD4 Count. 
TOXOPLASMOSIS 
• In this study  9 cases of toxoplasmosis was reported.  
• Mean CD4count was 53.11 cells. 
• Only 1 patient had CD4 count greater than 100,5 had below 50 
• P value was .001 so significant association was found between 
toxoplasmosis and CD4 COUNT. 
                      CRYPTOCOCCAL MENINGITIS 
Only 2 cases were observed 
• Mean CD4    count was 112 
                                      
 
 
  
CONCLUSION 
The following are the conclusion drawn from this study: 
 The percentage of HIV patients having neurological manifestation 
is 11 % over 12 month study period from august 2013 to august 
2014 . 
 
 Neurological manifestations heralded HIV in 61 % of patients. 
 
 Young ad s are mainly affected. 
 
 Sexual activity with CSWs is the major mode of transmission. 
 
 Meningitis was the commonest manifestation with 70% of the 
patients. 52 out of 74 patients comprising of  cases 61% Tubercular 
Meningitis,  cases, 6.7% bacterial meningitis, 2.7%-Cryptococcal 
Meningitis. others were: Toxoplasmosis (12%),Stroke-
(8%),Tuberculoma(4.05%),Bell’s palsy(1.35%), Myelopathy 
(1.35%),GBS (1.35%). 
 
 Tuberculosis is the commonest disease affecting nervous system 
(48/74) (65%)with 3 of these patients having intracranial space 
occupying lesion (tuberculoma) and rest is meningitis. 
 CD4 count has strong correlation with development of TB 
meningitis(212),toxoplasmosis(53.16),cva(436),bacterialmeningitis
(217),myelopathy(79),cryptococcal meningitis(123),PML(170). 
 
 High index of suspicion is necessary to detect HIV in patients 
presenting with neurological symptom and to diagnose and treat 
the underlying cause 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
74  patients of the approximately 672 patients admitted in our hospital 
had Neurological manifestations, prevalence of more than 11%. Patients 
age ranged from 21  years to 51 years with Female:  Male ratio – 1: 2.2. 
This indicates the High Prevalence of HIV in the economically 
productive age group, causes burden to the national economy. More than 
50% of the patients presented late in the disease process this indicates the 
lack of  awareness and fear of social stigma attached to this disease. 
61 percent of the patients who presented with neurological pathology and 
were diagnosed to have HIV infection/AIDS. 
Meningitis was the commonest Neurological presentation in HIV 
infection in this study around 70%. 
Tuberculosis is the single most common infection affecting CNS( 
64%.) Headache, fever and altered sensorium were commonest symptoms 
in HIV patients with Neurological pathology. 
CD4 count less than 200 was seen in 24 of  these patients(32%).others 
above 200 but below 500.so there is strong association between 
development of opportunistic infection and CD4 count. 
As compared to western literature CNS TB was the commonest 
disease associated with HIV infections in our study. It was the presenting 
pathology in 64% of the cases. It was associated with Pulmonary TB in 7 
of  the total cases. 4% patients showed Space occupying lesion.. 
Mean CD4 Count among th HIV patients observed to be 210.7,most of 
the opportunistic infectionss arise when CD4 count goes below 500.There 
is strong correlation between development of opportunistic infections and 
declining CD4 counts.so  monitoring is required so as to give adequate 
prophylaxis. 
       In my study no case of Peripheral Neuropathy was detected even 
though it has high prevalence in developed countries and probably due to 
anti-retroviral drugs being the cause. 
 
 
LIMITATIONS: Due to cost constraints  for opportunistic infections 
were done in limited number of patients and due to unavailability of PCR, 
steriotactic biopsy and other advanced investigating modalities all 
patients could not be investigated completely. 
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ANNEXURE - I 
DATA COLLECTION FORM 
BIODATA OF THE SUBJECT 
• Name of the subject: 
• Age: 
• Sex: 
• OP/IP/MRD No: 
• Study Subject no.: 
• Date of examination: 
• Native of: 
DIAGNOSIS 
• Incidental – Yes/No 
• If no, presenting complaint –  
• Associated complaints –  
• HIV status: Known / Newly detected 
• Date of Diagnosis of HIV: 
• Place of diagnosis: 
CLINICAL MANIFESTATIONS: 
• Altered sensorium   () 
• Bladder disturbances  ( ) 
• Convulsions   () 
• Cranial n. involvement  ( ) 
• Changes in Mental state  ( ) 
• Diarrhea   ( ) 
• Giddiness    ( ) 
• Focal deficits  ( ) 
• Fever    ( ) 
• Gait disturbance   ( ) 
• Headache    ( ) 
• Involuntary movements  ( ) 
• Loss of memory   ( ) 
• Visual changes  ( ) 
• Tingling    ( ) 
• Numbness    ( ) 
• Weight loss    ( ) 
• Weakness    ( ) 
• Vomiting    ( ). 
• Others 
NEUROLOGICALMANIFESTATIONS: 
• Altered sensorium: Drowsy/Delirius/Stupour/Unconscious 
• Convulsions: No. of episodes  ,Duration of each episode ,,Aura ,Tonic 
clonic/Focal/other Asso.features 
• Cranial nerve palsy: Diplopia / Dysarthria / Facial asymmetry /Vertigo 
/tinnitus / Deafness / Hoarseness /Dysphagia /Regurgitation 
• Changes in Mental state/Memory/Emotions/Speech 
• Focal deficit/Weakness: Part of the body involved ,Progress,Severity 
• Sensations: Absent: Part of the body involved ,Onset ,Progress ,Severity 
Tingling/Numbness 
• Involuntary movements: Part of the body involved Onset  ,Progres 
,Severity 
• Fever: Duration ,Degree ,Type-continuous/intermittent/remittent 
Asso.features-chills/rigors 
• Headache: Duration  ,Type-throbbing/dull aching 
,Unilatral/BilatralDiural Variation 
• Vomiting: No of episodes Type-projectile/non projectile ,Blood 
stained/Bilious 
• Loss of weight: Percentage Duration 
PAST HISTORY 
• Co-morbidities: DM, HTN, DLP, CAD, CVA, COPD, BA 
• Similar complaints Y / N 
• Admissions: 
• h/o contact: 
• h/o surgery: 
• Blood transfusion: 
• TB, HTN, DM, other STDs 
Drug/Treatment History: 
• Drugs used previously: 
• Current therapy: 
Personal History: 
Marital status : 
Married/Unmarried 
Diet   : Veg/Mixed 
Appetite  : Normal/Decreased 
Sleep   : Normal/Disturbed 
Bowel  : 
Normal/Diarrhea/Constipation 
Micturition : 
Normal/Retention/Incontinence 
Smoker  : Yes/No 
Alcoholic  : Yes/no 
Others   : 
 
 
 
Family History: 
HIV     : 
Other STDs    : 
General Physical Examination: 
Sensorium 
Built      
Weight 
Posture: 
Spine: 
Gait   
Meningism 
P__ I__  C__ C__  L__  E__ 
Lymphadenopathy: Y / N   
Site: 
Size: 
No. 
Discrete/Matted 
Soft/Firm/Hard
 
Vitals 
Pulse: 
BP: 
RR: 
Temp:
SYSTEMIC EXAMINATION: 
CNS: 
Higher Mental Functions: Normal 
Conscious/Unconscious/Drowsy/Stuporous/Delirious 
Emotional State: Hostile/Depressed/Euphoric 
Memory: Preserved/Affected 
Oriented/Disoriented 
Speech: Normal/Dysphasia/Dysarthria 
Cranial Nerves : 
• Olfactory: Normal/Abnormal 
• Optic: Normal    
Visual acuity     
Field of vision    
Color vision    
Fundus      
Light reflex  
Accommodation reflex 
• Occulomotor: 
Normal/Abnormal 
• Trochlear: Normal/Abnormal 
• Abducent: Normal/Abnormal 
• Trigeminal: 
Normal/Abnormal 
• Facial:Normal / Abnormal 
• Vestibulocochlear:Normal / 
Abnormal 
• Glossopharyngeal: Normal / 
Abnormal 
• Vagus: Normal / Abnormal 
• Spinal Accessory: Normal / 
Abnormal 
• Hypoglossal:Normal / 
Abnormal 
Motor system: 
RIGHT     LEFT 
• Nutrition/Bulk   
• Tone 
• Power 
• Co-ordination 
• Gait: 
Sensorysystem: 
 
• Superficial sensations: 
• Deep sensations: 
• Cortical sensations: 
Superficial reflexes: 
• Abdominal:  
• Cremasteric: 
• Bulbocavernous:  
• Anal:  
• Plantars:  
 
Deep reflexes: 
• Biceps : 
• Supinator : 
• Triceps : 
• Knee : 
• Ankle: 
(Absent; 1- Present; 2- Brisk; 3- Very Brisk; 4- Clonus) 
 
Cerebellar Signs: 
Other Systems 
• RS : 
• CVS : 
• P/A : 
INVESTIGATIONS: 
• Hb%:  
• TC: ___cells/cumm 
• N-___% 
• L-___% 
• E-___% 
• M-___% 
• B-___% 
• Total lymphocyte 
count:____cells/cumm 
• ESR: 
• Urine: 
• Stool: 
• Absolute CD4 count: 
• VDRL
 
CSF: Cell count and type 
• Gram stain 
• AFB 
• Protein 
• Glucose 
• Chloride 
• Indian ink preparation for Cryptococci RADIOLOGY 
• X-ray chest : 
• CT SCAN: 
DIAGNOSED OPPURTUNISTIC INFECTIONS: 
 
 
 
 
 
 
  
ANNEXURE-II 
INFORMED CONSENT 
Subject identification number for this study: _____________________________________ 
Title of the project: A study on neurological manifestations of HIV with regard to CD4 count. 
Name of the principal investigator: Dr.Sreedevi S 
I have received the information sheet on the above study and have read and/or understood the 
written information. 
I have been given the chance to discuss the study and ask questions. 
I consent to take part in the study and I am aware that my participation is voluntary. 
I understand that I may withdraw at any time without this affecting my future care. 
I understand that the information collected about me from my participation in this research 
and sections of any of my medical notes may be looked at by responsible persons (ethics 
committee members/ regulatory authorities). I give access to these individuals to have access 
to my records. 
I understand I will receive a copy of the patient information sheet and the informed consent 
form. 
 
____________________________________  ________________ 
Signature/ Thumb Impression of the subject    Date 
 
____________________________________ 
Printed name of the subject in capitals  
 
____________________________________  ________________ 
Signature/ Thumb Impression of the legally     Date 
acceptable representative subject   
 
   The legally acceptable representative signature should be added if the 
subject is a minor or is unable to sign by themselves. The relationship between the subject 
and the legally acceptable representative should be stated. The impartial witness signature 
should be added if the subject be stated. The impartial witness signature should be added if 
subject/legally acceptable representative us unable to read and write and consent should be 
obtained in his presence.  
 ____________________________________________________ 
Printed name of the legally acceptable representative in capitals 
 
____________________________________________________ 
Relationship of the legally acceptable representative to subject in capitals 
 
________________________________     _______________ 
Signature of the person conducting the      Date 
informed consent discussion 
 
____________________________________ 
Printed name of the person conducting the  
informed consent discussion in capitals 
 
 
____________________________________    _______________ 
Signature of the impartial witness in capitals      Date 
 
 
____________________________________ 
Printed name of the impartial witness in capitals 
 
 
  
ANNEXURE-III 
MASTERCHART 
KEY TO MASTER CHART 
 
 
ALTS Altered sensorium 
AN/AbN Abnormal 
ANM Abnormal MRI 
B Brisk 
BM Bacterial Meningitis 
BNHO Bilateral Nonhomogenous opacity 
BP Bell’s Palsy 
C Could Not be tested 
CBE Coimbatore 
CE Cerebral edema 
CM CryptococcalMeningitis 
CTBLM CNS Tuberculoma 
CXR Chest x ray 
D Decreased 
DL Delirious 
DR Drowsy 
EM Emphysematous 
F Female 
FND Focal Neurological deficit 
H/W House wife 
HC Hydrocephalous 
Hk Healed kochs 
HL Hypo denseLesion 
HMF Higher mentalfunctions 
IE Inflammatory Exudate 
IIC IndianInk for Cryptococci 
LULI Left lower lobe infiltrates 
LUZI Left upper zoneinfiltrates 
M Male 
MEL Multiple enhancinglesion 
ML Multiple 
ML Migrant Labourer 
MLP Myelopathy 
N New 
N Negative/Normal 
ND Not done 
NI North Indian 
O Old 
P Positive 
PE Papilledema 
REL Ring enhancing lesion 
RMZI Right middle zone opacity 
RS Respiratory system 
RULI Right upper lobe infiltrates 
RUZO Right upper zone opacity 
S Single 
SE Sexual 
SEL Singleenhancinglesion 
SI South Indian - outside TN 
SO Self-occupation 
TN TamiliaN outside Coimbatore 
U Unknown 
Y Yes 
 
